

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C07D 263/32, 413/10, A61K 31/421, 31/422, C07D 413/12		A1	(11) International Publication Number: WO 00/18744
			(43) International Publication Date: 6 April 2000 (06.04.00)
(21) International Application Number: PCT/JP99/05212		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 24 September 1999 (24.09.99)		<p>Published With international search report.</p>	
(30) Priority Data: PP 6176 25 September 1998 (25.09.98) AU PP 9822 19 April 1999 (19.04.99) AU			
(71) Applicant (for all designated States except US): FUJISAWA PHARMACEUTICAL CO., LTD. [JP/JP]; 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP).			
(72) Inventors; and (75) Inventors/Applicants (for US only): HATTORI, Kouji [JP/JP]; 7-1-915, Sumiregaoka 1-chome, Takarazuka-shi, Hyogo 665-0847 (JP). TANAKA, Akira [JP/JP]; 9-10-302, Nakanochi, Takarazuka-shi, Hyogo 665-0056 (JP). KONO, Yutaka [JP/JP]; 12-13-305, Funakicho, Ibaraki-shi, Osaka 567-0828 (JP). NAKAZATO, Shoko [JP/JP]; 4-20-214, Kumanochi, Nishinomiya-shi, Hyogo 663-8103 (JP).			
(74) Agents: KOTANI, Etsuji et al.; Sumisei Naniwasuji Honmachi Building, 3-2, Utsubohonmachi 2-chome, Nishi-ku, Osaka-shi, Osaka 550-0004 (JP).			
(54) Title: OXAZOLE COMPOUNDS AS PROSTAGLANDIN E2 AGONISTS OR ANTAGONISTS			
<p style="text-align: right;">(I)</p>			
(57) Abstract			
<p>Oxazole compounds of formula (I), wherein R¹ is aryl which may be substituted with halogen(s), R² is aryl which may be substituted with halogen(s), X is single bond, (a) or SO₂, R³ and R⁴ are independently hydrogen or suitable substituent, (wherein X is (a), neither R³ nor R⁴ is hydrogen), R³ and R⁴ may be linked together to form (b), (b) is N-containing heterocyclic group which may be substituted with one or more suitable substituent(s), R⁵ is hydrogen, etc., A¹ is lower alkylene or single bond, (c) is cyclo(C₃-C₉)alkane or cyclo(C₅-C₉)alkene, or a pro-drug thereof, or a pharmaceutically acceptable salt thereof, which are useful as medicament.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

DESCRIPTION

OXAZOLE COMPOUNDS AS PROSTAGLANDIN E₂ AGONISTS OR
ANTAGONISTS

TECHNICAL FIELD

This invention relates to prostaglandin E₂ agonist or antagonist such as oxazole compounds and pharmaceutically acceptable salts thereof which are useful as a medicament.

BACKGROUND ART

Some oxazole compounds are known, for example, in WO 95/17393, WO 95/24393 and WO 97/03973.

DISCLOSURE OF INVENTION

This invention relates to oxazole compounds. More particularly, this invention relates to oxazole compounds and pharmaceutically acceptable salts thereof which are useful as prostaglandin E₂ (hereinafter described as PGE₂) agonist or antagonists.

Accordingly, one object of this invention is to provide new and useful oxazole compounds and pharmaceutically acceptable salts thereof.

Another object of this invention is to provide processes for preparing of the oxazole compounds or pharmaceutically acceptable salts thereof.


A further object of this invention is to provide a pharmaceutical composition containing, as an active ingredient, said oxazole compounds or pharmaceutically acceptable salts thereof.

A still further object of this invention is to provide use of

the oxazole compounds and pharmaceutically acceptable salts thereof for the manufacture of medicaments for treating or preventing PGE₂ mediated diseases.

A still more further object of this invention is to provide use of prostaglandin E₂ antagonist (especially, EP4 receptor blocker) such as oxazole compounds and pharmaceutically acceptable salts thereof for the manufacture of medicaments for treating or preventing mesangial proliferative glomerulonephritis.

The oxazole compounds of this invention can be represented by the following formula (I) :



wherein

R¹ is aryl which may be substituted with halogen(s),

R² is aryl which may be substituted with halogen(s),

X is single bond, $\text{C}(=\text{O})$ or SO_2 ,

R³ and R⁴ are independently hydrogen or suitable substituent,

(wherein X is $\text{C}(=\text{O})$, neither R³ nor R⁴ is hydrogen),

R³ and R⁴ may be linked together to form $-\text{N} \bigcirc$,

$-\text{N} \bigcirc$ is N-containing heterocyclic group which may be

substituted with one or more suitable substituent(s),

R⁵ is

- (1) hydrogen,
- (2) hydroxy,
- (3) carboxy, or
- (4) protected carboxy,

A¹ is lower alkylene or single bond,

A² is cyclo(C₃-C₉)alkane or cyclo(C₅-C₉)alkene,

or a pro-drug thereof, or a pharmaceutically acceptable salt thereof.

The compounds of formula (I) may contain one or more asymmetric centers and thus they can exist as enantiomers or diastereoisomers. Furthermore certain compounds of formula (I) which contain alkenyl groups may exist as cis- or trans-isomers. In each instance, the invention includes both mixtures and separate individual isomers.


The compounds of the formula (I) may also exist in tautomeric forms and the invention includes both mixtures and separate individual tautomers.

The compound of the formula (I) and a salt thereof can be in a form of a solvate, which is included within the scope of the present invention. The solvate preferably include a hydrate and an ethanolate.


Also included in the scope of invention are radiolabelled derivatives of compounds of formula (I) which are suitable for biological studies, and any form of the crystal of the compound (I).

According to the present invention, the oxazole compounds (I) or a pharmaceutically acceptable salt thereof can be prepared by the following Processes 1 to 5.

Process 1




Process 2



(V)

or a salt thereof



(VI)

or a salt thereof


(III)

or its reactive derivative


at the amino group

or a salt thereof


Process 3



Process 4



Process 5



wherein

R^1 is aryl which may be substituted with halogen(s),

R^2 is aryl which may be substituted with halogen(s),

X is single bond, $\text{C}(=\text{O})$ or SO_2 ,

R^3 and R^4 are independently hydrogen or suitable substituent,

(wherein X is $\text{C}(=\text{O})$, neither R^3 nor R^4 is hydrogen),

R^3 and R^4 may be linked together to form $-\text{N}(\text{ring})-$,

$-\text{N}(\text{ring})-$ is N-containing heterocyclic group which may be substituted with one or more suitable substituent(s),

R^{4*} is acyl which may be substituted with aryl,

R^5 is

- (1) hydrogen,
- (2) hydroxy,
- (3) carboxy, or
- (4) protected carboxy,

- R⁶ is acyl or hydroxy,
R⁷ is lower alkyl, ar(lower)alkyl or aryl,
A¹ is lower alkylene or single bond,
(A²) is cyclo(C₃-C₉)alkane or cyclo(C₅-C₉)alkene,

The starting compounds (II) or a salt thereof can be prepared according to a similar method described in WO 95/17393, below-mentioned Preparations, and the like.

In the above and subsequent descriptions of the present specification, suitable examples and illustrations of the various definitions which the present invention includes within the scope thereof are explained in detail as follows.

Suitable "aryl" and aryl moiety in the terms "ar(lower)alkyl", "aryloxy", "ar(lower)alkenyl", "arylsulfonyl", "ar(lower)arylsulfonyl", "ar(lower)alkylsulfonyl", and "aryl oxysulfonyl" may include phenyl, lower alkylphenyl (e.g., tolyl, ethylphenyl, propylphenyl, etc.), naphthyl or the like.

Suitable "halogen" may include fluorine, chlorine, bromine, or iodine.

The term "lower" is intended to mean 1 to 6 carbon atom(s), unless otherwise indicated.

Suitable "lower alkyl" and lower alkyl moiety in the terms "lower alkylamino", "ar(lower)alkyl", "carboxy(lower)alkyl", "hydroxy(lower)alkyl", "ar(lower)alkylsulfonyl", and lower alkylsulfonyl may include straight or branched one having 1 to 6 carbon atom(s), such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl, t-pentyl, hexyl or the like,

preferably one having 1 to 4 carbon atom(s).

Suitable "lower alkylamino" may include mono- or di-(lower)alkylamino, such as methylamino, dimethylamino, ethylamino, diethylamino, or the like.

Suitable "lower alkoxy" and lower alkoxy moiety in the term "hydroxy(lower)alkoxy" may include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, t-butoxy, pentyloxy, t-pentyloxy, hexyloxy, or the like, preferably methoxy.

Suitable "heterocyclic group" may include saturated or unsaturated, monocyclic or polycyclic heterocyclic group containing at least one nitrogen atom. And especially preferable heterocyclic ring containing nitrogen may be ones such as

unsaturated 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s), for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl and its N-oxide, pyrimidinyl, pyrazinyl, dihydropyridazinyl, tetrahydropyridazinyl, triazolyl (e.g., 1H-1,2,4-triazolyl, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.), tetrazolyl (e.g., 1H-tetrazolyl, 2H-tetrazolyl, etc.), dihydrotriazinyl (e.g., 4,5-dihydro-1,2,4-triazinyl, 2,5-dihydro-1,2,4-triazinyl, etc.), etc., ;

saturated 3 to 8-membered heteromonocyclic group containing 1 to 4 nitrogen atom(s), for example, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, azacycloheptyl, azacyclooctyl, perhydroazepinyl, etc., ;

unsaturated condensed heterocyclic group containing 1 to 5 nitrogen atom(s), for example, indolyl, 2,3-dihydroindolyl, isoindolyl, indolinyl, indazolyl, isoindolinyl, indolizinyl,

benzimidazolyl, quinolyl, 1,2,3,4-tetrahydroquinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridyl, tetrazolopyridazinyl (e.g., tetrazolo[1,5-b]pyridazinyl, etc.), dihydrotriazolopyridazinyl, etc.;

unsaturated 3 to 8-membered heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, oxazolyl, isoxazolyl, dihydroisoxazolyl, oxadiazolyl (e.g., 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 2,5-oxadiazolyl, etc.), etc.;

saturated 3 to 8-membered heteromonocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, morpholino, etc.;

unsaturated condensed heterocyclic group containing 1 to 2 oxygen atom(s) and 1 to 3 nitrogen atom(s), for example, benzoxazolyl, benzoxadiazolyl, etc.;

unsaturated 3 to 8-membered heteromonocyclic group containing 1 to 2 sulfur atom(s), for example, thienyl, thiopynyl, etc.;

unsaturated 3 to 8-membered heteromonocyclic group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, thiazolyl, isothiazolyl, thiazolinyl, thiadiazolyl (e.g., 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,2,3-thiadiazolyl), etc.;

saturated 3 to 8-membered heteromonocyclic group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, thiazolidinyl, etc.;

unsaturated condensed heteromonocyclic group containing 1 to 2 sulfur atom(s) and 1 to 3 nitrogen atom(s), for example, benzothiazolyl, benzothiadiazolyl, etc., and the like.

Suitable acyl and acyl moiety in the terms of "acylamino"

and "acyloxy" may include aliphatic acyl group and acyl group containing an aromatic or heterocyclic ring.

And, suitable examples of the said acyl may be lower alkanoyl (e.g. formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, oxalyl, succinyl, pivaloyl, etc.); lower alkenoyl (e.g., propionyl, 2-methylpropionyl, butenoyl, or the like, preferably one having 3 to 4 carbon atom(s)); aroyl (benzoyl, naphthoyl, etc.); lower alkoxyaroyl (methoxyphenylcarbonyl, ethoxyphenylcarbonyl, propoxyphenylcarbonyl, isopropoxyphenylcarbonyl, methoxynaphthylcarbonyl, ethoxynaphthylcarbonyl, propoxynaphthylcarbonyl, isopropoxynaphthylcarbonyl, etc.); heterocyclic carbonyl ("heterocyclic moiety" in the term "heterocyclic carbonyl" can be referred above); bridged cyclic(lower)alkanecarbonyl (bicyclo[2.2.1]hept-2-yl-carbonyl, bicyclo[3.2.1]oct-2-yl-carbonyl, bicyclo[3.2.2]non-2-yl-carbonyl, bicyclo[3.2.2]non-3-yl-carbonyl, bicyclo[4.3.2]undec-2-yl-carbonyl, bicyclo[4.3.2]undec-3-yl-carbonyl, bicyclo[2.2.2]oct-2-en-2-yl-carbonyl, bicyclo[3.2.2]non-3-en-3-yl-carbonyl, tricyclo[5.3.1.1]dodec-2-yl-carbonyl, tricyclo[5.3.1.1]dodec-3-yl-carbonyl, adamantylcarbonyl, etc.); cyclo(lower)-alkanecarbonyl (cyclopropanecarbonyl, cyclobutanecarbonyl, cyclopentanecarbonyl, cyclohexanecarbonyl, etc.), carbamoyl which may be substituted with mono- or di-(lower)alkyl (e.g. dimethylcarbamoyl, etc.) and the like.

Suitable "cyclo(lower)alkyl" may include cyclopropyl, cyclopentyl, cyclobutyl, cyclohexyl, or the like.

Suitable "cyclo(lower)alkenyl" may include cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclononenyl, or the

like.

Suitable "protected carboxy" may include carboxylate, esterified carboxy, or the like.

Suitable example of the ester moiety of an esterified carboxy may be the ones such as lower alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, etc.) which may have at least one suitable substituent(s), for example, lower alkanoyloxy(lower)alkyl [e.g., acetoxymethyl, butyryloxymethyl, valeryloxymethyl, pivaloyloxymethyl, etc.], halo(lower)alkyl (e.g., 2-iodoethyl, 2,2,2-trichloroethyl, etc.); lower alkenyl (e.g., vinyl, allyl, etc.); lower alkynyl (e.g., ethynyl, propynyl, etc.); ar(lower)alkyl which may have at least one suitable substituent(s) (e.g., benzyl, 4-methoxybenzyl, 4-nitrobenzyl, phenethyl, trityl, etc.); aryl which may have at least one suitable substituent(s) (e.g., phenyl, tolyl, 4-chlorophenyl, tert-butylphenyl, xylyl, mesityl, cumenyl, etc.); phthalidyl; or the like.

Suitable "lower alkylene" may include straight or branched one having 1 to 6 carbon atom(s), such as methylene, ethylene, trimethylene, tetramethylene, pentamethylene and hexamethylene, preferably one having 1 to 3 carbon atom(s), more preferably methylene.

Suitable "cyclo(C₃-C₉)alkane" may include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, cyclononane, or the like, preferably one having 5 to 7 carbon atoms.

Suitable "cyclo(C₅-C₉)alkene" may include cyclopentene, cyclohexene, cycloheptene, cyclooctene, cyclononene, or the like, preferably one having 5 to 7 carbon atoms.

Preferred embodiments of the oxazole compounds (I) are as follows :

wherein

R¹ is aryl which may be substituted with halogen(s),

R² is aryl which may be substituted with halogen(s),

X is single bond, $\text{C} \begin{smallmatrix} \parallel \\ \text{O} \end{smallmatrix}$ or SO₂,

R³ and R⁴ are independently

- (1) hydrogen;
- (2) hydroxy;
- (3) lower alkyl which may be substituted with one or more substituent(s) selected from the group consisting of:

- (a) hydroxy,
- (b) cyano,
- (c) lower alkoxy,
- (d) hydroxy(lower)alkoxy,
- (e) cyclo(lower)alkyl,
- (f) cyclo(lower)alkenyl,
- (g) amino,
- (h) lower alkylamino,
- (i) carbamoyl,
- (j) carboxy,
- (k) protected carboxy,
- (l) heterocyclic group optionally substituted with ar(lower)alkyl or oxo, and
- (m) aryl optionally substituted with
hydroxy,
carboxy,
protected carboxy,

- carboxy(lower)alkyl, or
lower alkoxy which may be substituted with
carboxy or protected carboxy;
- (4) lower alkoxy which may be substituted with aryl(s);
- (5) aryl which may be substituted with one or more
substituent(s) selected from the group consisting of:
- (a) aryloxy,
 - (b) acylamino, and
 - (c) carbamoyl;
- (6) cyclo(lower)alkyl which may be substituted with
hydroxy(s);
- (7) arylsulfonyl;
- (8) ar(lower)alkylsulfonyl;
- (9) lower alkylsulfonyl;
- (10) aryloxysulfonyl;
- (11) heterocyclic group which may be substituted with
one or more substituent(s) selected from the group
consisting of:
- (a) ar(lower)alkyl,
 - (b) aryl,
 - (c) protected carboxy,
 - (d) lower alkyl, and
 - (e) oxo;
- (12) acyl which may be substituted with aryl; or
- (13) carbamoyl which may be substituted with acyl,
ar(lower)alkyl, or arylsulfonyl,

(wherein X is $\text{C}=\text{O}$, neither R^3 nor R^4 is hydrogen),

R^3 and R^4 may be linked together to form $-\text{N}\bigcirc$,

$-\text{N}\bigcirc$ is N-containing heterocyclic group which may be

substituted with one or more substituent(s) selected from the group consisting of:

- (1) lower alkyl,
- (2) aryl,
- (3) protected carboxy,
- (4) hydroxy(lower)alkyl,
- (5) ar(lower)alkyl,
- (6) hydroxy,
- (7) oxo, and
- (8) lower alkylamino,

R⁵ is

- (1) hydrogen,
- (2) hydroxy,
- (3) carboxy, or
- (4) protected carboxy,

A¹ is lower alkylene or single bond,

A² is cyclo(C₃-C₉)alkane or cyclo(C₃-C₉)alkene,

or a pro-drug thereof, or a pharmaceutically acceptable salt thereof.

More preferred embodiments of the oxazole compounds (I) are as follows :

wherein

R¹ is aryl,

R² is aryl,

X is single bond, $\overset{\text{C}}{\parallel}$ or SO₂,
O

R³ and R⁴ are independently

- (1) hydrogen;
- (2) hydroxy;
- (3) lower alkyl which may be substituted with one or more substituent(s) selected from the group consisting of:
 - (a) hydroxy,
 - (b) cyano,
 - (c) lower alkoxy,
 - (d) hydroxy(lower)alkoxy,
 - (e) cyclo(lower)alkyl,
 - (f) cyclo(lower)alkenyl,
 - (g) amino,
 - (h) lower alkylamino,
 - (i) carbamoyl,
 - (j) carboxy,
 - (k) protected carboxy,
 - (l) heterocyclic group optionally substituted with ar(lower)alkyl or oxo, and
 - (m) aryl optionally substituted with
 - hydroxy,
 - carboxy,
 - protected carboxy,
 - carboxy(lower)alkyl, or
 - lower alkoxy which may be substituted with carboxy or protected carboxy;
- (4) lower alkoxy which may be substituted with aryl(s);
- (5) aryl which may be substituted with one or more substituent(s) selected from the group consisting of:
 - (a) aryloxy,
 - (b) acylamino, and

- (c) carbamoyl;
 - (6) cyclo(lower)alkyl which may be substituted with hydroxy(s);
 - (7) arylsulfonyl;
 - (8) ar(lower)alkylsulfonyl;
 - (9) lower alkylsulfonyl;
 - (10) aryloxysulfonyl;
 - (11) heterocyclic group which may be substituted with one or more substituent(s) selected from the group consisting of:
 - (a) ar(lower)alkyl,
 - (b) aryl,
 - (c) protected carboxy,
 - (d) lower alkyl, and
 - (e) oxo;
 - (12) acyl which may be substituted with aryl; or
 - (13) carbamoyl which may be substituted with acyl, ar(lower)alkyl, or arylsulfonyl,
- (wherein X is $\text{C}=\text{O}$, neither R^3 nor R^4 is hydrogen),

R^3 and R^4 may be linked together to form $-\text{N}\bigcirc$,

$-\text{N}\bigcirc$ is N-containing heterocyclic group which may be substituted with one or more substituent(s) selected from the group consisting of:

- (1) lower alkyl,
- (2) aryl,
- (3) protected carboxy,
- (4) hydroxy(lower)alkyl,
- (5) ar(lower)alkyl,
- (6) hydroxy,

(7) oxo, and
(8) lower alkylamino,
 R^5 is hydrogen,
 A^1 is lower alkylene,
 A^2 is

- (1) cyclohexane,
- (2) cyclohexene,
- (3) cyclopentane, or
- (4) cyclopentene,

or a pro-drug thereof, or a pharmaceutically acceptable salt thereof.

Furthermore preferred embodiments of the oxazole compounds (I) are as follows :

wherein

R^1 is phenyl,

R^2 is phenyl,

X is $\begin{array}{c} \text{C} \\ \parallel \\ \text{O} \end{array}$ or SO_2 ,

R^3 and R^4 are independently

- (1) hydrogen;
- (2) lower alkyl which may be substituted with one or more substituent(s) selected from the group consisting of:
 - (a) hydroxy,
 - (b) heterocyclic group, and
 - (c) phenyl;
- (3) lower alkoxy which may be substituted with phenyl;

or

(4) phenyl which may be substituted with phenyloxy;
(wherein X is C, neither R³ nor R⁴ is hydrogen),



R³ and R⁴ are linked together to form -N \bigcirc ,

-N \bigcirc is N-containing heterocyclic group;

R⁵ is hydrogen,

A¹ is methylene,

\bigcirc A² is

- (1) cyclohexane,
- (2) cyclohexene,
- (3) cyclopentane, or
- (4) cyclopentene,

or a pro-drug thereof, or a pharmaceutically acceptable salt thereof.

The most preferred embodiment of the oxazole compounds
(I) is N-[(2-hydroxy-2-phenyl)ethyl]-3-{[(1S,2R)-2-(4,5-diphenyloxazol-2-yl)-1-cyclopentyl]methyl}benzamide, N-(2,2-diphenylethyl)-3-{[(1S,2R)-2-(4,5-diphenyl-oxazol-2-yl)-1-cyclopentyl]methyl}benzamide, N-benzyloxy-3-{[(1S)-2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzamide or N-benzylsulfonyl-3-{[(1S)-2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzamide.

The processes for preparing the object and starting compounds of the present invention are explained in detail in the

following.

Process 1

The compound (IV) or a salt thereof can be prepared by reacting the compound (II) or a salt thereof, with the compound (III) or its reactive derivative at the amino group or a salt thereof.

Suitable reactive derivative of the compound (III) may include Schiff's base type amino or its tautomeric enamine type isomer formed by the reaction of the compound (III) with a carbonyl compound such as aldehyde, ketone or the like; a silyl derivative formed by the reaction of the compound (III) with a silylating reagent such as N,O-bis(trimethylsilyl)acetamide, N-trimethylsilylacetamide, or the like.

Suitable reactive derivative of the compound (II) may include an acid chloride, an acid anhydride, an activated amide, an activated ester, or the like.

Suitable acid anhydride may be a symmetric anhydride or a mixed acid anhydride with an acid such as substituted phosphoric acid (e.g., dialkylphosphoric acid, phenylphosphoric acid, diphenylphosphoric acid, dibenzylphosphoric acid, halogenated phosphoric acid, etc.), dialkylphosphorous acid, sulfuric acid, thiosulfuric acid, alkanesulfonic acid (e.g., methanesulfonic acid, ethanesulfonic acid, etc.), alkylcarbonic acid, aliphatic carboxylic acid (e.g., pivalic acid, pentanoic acid, isopentanoic acid, etc.); aromatic carboxylic acid (e.g., benzoic acid, chlorobenzoic acid, fluorobenzoic acid, nitrobenzoic acid, etc.), or the like.

Suitable activated amide may be imidazolylamide, 4-substituted imidazolylamide, dimethylpyrazolylamide,

triazolylamide, tetrazolylamide, or the like.

Suitable activated ester may be dimethyliminomethyl $[(CH_3)_2N^+=CH-]$ ester, vinyl ester, propargyl ester, 4-nitrophenyl ester, 2,4-dinitrophenyl ester, trichlorophenyl ester, pentachlorophenyl ester, pentafluorophenyl ester, methanesulfonylphenyl ester, phenyl thioester, p-nitrophenyl thioester, carboxymethyl thioester, pyranyl ester, pyridyl ester, 8-quinolyl thioester, an activated ester with a N-hydroxy compound (e.g., N,N-dimethylhydroxylamine, 1-hydroxy-2H-pyridone, N-hydroxysuccinimido, N-hydroxybenzotrioxazole, N-hydroxyphthalimide, etc.), or the like.

These reactive derivatives can optionally be selected from them according to the kind of compound (II) to be used.

When the compound (II) is used in free acid form or its salt form in the reaction, the reaction is preferably carried out in the presence of condensing agent.

Suitable condensing agent may include a carbodiimide (e.g., N,N'-dicyclohexylcarbodiimido, N-cyclohexyl-N'-(4-diethylaminocyclohexyl) carbodiimido, N-ethyl-N'-(3-dimethylaminopropyl)carbodiimido or its hydrochloride) diphenylphosphinic azido, diphenylphosphinic chloride, diethylphosphoryl cyanide, bis(2-oxo-3-oxazolidinyl)phosphinic chloride, N,N'-carbonyldiimidoxazole, 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline, cyanuric chloride, or the like.

The reaction may be also carried out in the presence of organic or inorganic base such as alkali metal carbonate, tri(lower)alkylamine, pyridine, N-(lower)alkylmorpholine, or the like.

The reaction is usually carried out in a conventional

solvent such as water, acetone, alcohol [e.g., methanol, ethanol, isopropyl alcohol, etc.], tetrahydrofuran, dioxane, toluene, methylene chloride, chloroform, N,N-dimethylformamide or any other organic solvents which do not adversely affect the reaction, or the mixture thereof.

The reaction temperature is not critical and the reaction is usually carried out under cooling to warming.

Suitable salts of the object compound (I) including the compounds (IV) and (V), and the compounds (II) and (V) are pharmaceutically acceptable conventional non-toxic salts and include a metal salt such as an alkali metal salt (e.g., sodium salt, potassium salt, etc.) and an alkaline earth metal salt (e.g., calcium salt, magnesium salt, etc.), an ammonium salt, an organic base salt (e.g., trimethylamine salt, triethylamine salt, pyridine salt, picoline salt, dicyclohexylamine salt, etc.), an organic acid salt (e.g., acetate, maleate, tartrate, methanesulfonate, benzenesulfonate, formate, toluenesulfonate, trifluoroacetate, etc.), an inorganic acid salt (e.g., hydrochloride, hydrobromide, sulfate, phosphate, etc.), a salt with an amino acid (e.g., arginine, aspartic acid, glutamic acid, etc.), or the like.

Process 2

The compound (VI) or a salt thereof can be prepared by reacting the compound (V) or a salt thereof, with the compound (III) or its reactive derivative at the amino group or a salt thereof.

This reaction can be referred to that of Examples 6-1 and

6-2.

Process 3

The compound (IX) or a salt thereof can be prepared by reacting the compound (VII) or a salt thereof, with the compound (VIII) or its reactive derivative at the carboxy group or a salt thereof.

Suitable reactive derivative at the carboxy group may include its halide (carbonyl chloride, carbonyl bromide, etc.), its anhydride, its activated ester and the like.

This reaction can be referred to that of Examples 7-1 and 7-2.

Process 4

The compound (XI) or a salt thereof can be prepared by reacting the compound (VII) or a salt thereof, with the compound (X) or a salt thereof.

This reaction can be referred to that of Examples 7-3, 7-4 and 7-5.

Process 5

The compound (XIII) or a salt thereof can be prepared by reacting the compound (VII) or a salt thereof, with the compound (XII) or its reactive derivative at the sulfo group or a salt thereof.

Suitable reactive derivative at the sulfo group may include its halide (sulfonyl chloride, etc.), its anhydride, its activated ester and the like.

This reaction can be referred to that of Example 7-6.

PGE₂ is known as one of the metabolites in an arachidonate cascade. And it is also known that it has various activities such as pain inducing activity, inflammatory activity, uterine contractile activity, a promoting effect on digestive peristalsis, an awaking activity, a suppressive effect on gastric acid secretion, hypotensive activity, blood platelet inhibition activity, bone-resorbing activity, angiogenic activity, or the like.

PGE₂-sensitive receptors have been sub-divided into four subtypes, EP1, EP2, EP3 and EP4, and these receptors have a wide distribution in various tissues. The effects associated with EP1 receptor are believed to be mediated by mobilization of Ca²⁺ from intracellular stores. The EP3 receptor is an example of promiscuous receptor that may couple to different second-messenger systems. Further, the effects associated with EP2 and EP4 receptors may be considered as inhibitory, and are believed to be associated with a stimulation of adenyl cyclase and an increase in levels of intracellular cyclic AMP. Especially, EP4 receptor may be considered to be associated with smooth muscle relaxation, anti-inflammatory or pro-inflammatory activities, lymphocyte differentiation, antiallergic activities, mesangial cell relaxation or proliferation, gastric or enteric mucus secretion, or the like.

The oxazole compounds represented by the formula (I) or its salts thereof possess binding activities to PGE₂-sensitive receptors, specifically to EP4 receptor, therefore they possess a PGE₂-antagonizing or PGE₂-inhibiting activity.

Therefore, the compounds represented by the formula (I) or its salts thereof are useful for preventing or treating a PGE₂ mediated diseases, especially a EP4 receptors-mediated diseases,

such as inflammatory conditions, various pains, or the like in human beings or animals.

More particularly, PGE₂ agonist or antagonist, such as the compounds represented by formula (I) and its salt thereof, are useful for treating or preventing inflammation and pain in joint and muscle (e.g., rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis, juvenile arthritis, etc.), inflammatory skin condition (e.g., sunburn, burns, eczema, dermatitis, etc.), inflammatory eye condition (e.g., conjunctivitis, etc.), lung disorder in which inflammation is involved (e.g., asthma, bronchitis, pigeon fancier's disease, farmer's lung, etc.), condition of the gastrointestinal tract associated with inflammation (e.g., aphthous ulcer, Crohn's disease, atopic gastritis, gastritis varioliforme, ulcerative colitis, coeliac disease, regional ileitis, irritable bowel syndrome, etc.), gingivitis, inflammation, pain and tumescence after operation or injury, pyrexia, pain and other conditions associated with inflammation, allergic disease, systemic lupus erythematosus, scleroderma, polymyositis, tendinitis, bursitis, periarteritis nodosa, rheumatic fever, Sjgren's syndrome, Behcet disease, thyroiditis, type I diabetes, diabetic complication (diabetic microangiopathy, diabetic retinopathy, diabetic neuropathy, etc.), nephrotic syndrome, aplastic anemia, myasthenia gravis, uveitis contact dermatitis, psoriasis, Kawasaki disease, sarcoidosis, Hodgkin's disease, Alzheimer's disease, kidney dysfunction (nephritis, nephritic syndrome, etc.), liver dysfunction (hepatitis, cirrhosis, etc.), gastrointestinal dysfunction (diarrhea, inflammatory bowel diseases, etc.) shock, bone disease characterized by abnormal bone metabolism such as osteoporosis (especially, postmenopausal osteoporosis), hyper-

calcemia, hyperparathyroidism, Paget's bone diseases, osteolysis, hypercalcemia of malignancy with or without bone metastases, rheumatoid arthritis, periodontitis, osteoarthritis, ostealgia, osteopenia, cancer cachexia, calculosis, lithiasis (especially, urolithiasis), solid carcinoma, or the like in human being or animal.

Furthermore particularly, PGE₂ antagonist (especially, EP4 receptor blocker) such as the compounds represented by formula (I) and its salt thereof are useful for treating or preventing mesangial proliferative glomerulonephritis.

Generally, nephritis is classified into two major categories: glomerulonephritis and interstitial nephritis. Among these, interstitial nephritis is additionally sub-classified as follows:

- (1) minimal change;
- (2) focal segmental glomerulosclerosis;
- (3) membranous nephropathy;
- (4) endocapillary proliferative glomerulonephritis;
- (5) mesangial proliferative glomerulonephritis;
- (6) membranoproliferative glomerulonephritis; and
- (7) crescentic glomerulonephritis.

The inventors of the present invention found that PGE₂ antagonist (especially EP4-receptor blocker) was effective for treating or preventing mesangial proliferative glomerulonephritis among the above-mentioned symptoms. Specifically, it is a new fact found by the inventors of the present invention that PGE₂ antagonist is effective for treating or preventing mesangial proliferative glomerulonephritis. The inventors of the present invention have confirmed that one of PGE₂ antagonist, namely, the compound of this invention, is

effective for treating or preventing mesangial proliferative glomerulonephritis, as evidenced below in Experiment Data.

The compound represented by the formula (I) or its salts thereof are also useful for the preparation of medicament having diuretic activity, which are useful for the preparation of drugs indicated treating or preventing various edema (e.g. cardiac edema, cerebral edema, etc.), hypertension such as malignant hypertension or the like, premenstrual tension, urinary calculus, oliguria such as the one caused by acute or chronic failure, hyperphosphaturia, or the like.

In order to show the utility of the object compound (I), pharmacological data of the representative compounds thereof are shown in the following.

Binding assay using expression of prostanoid receptor subtype

[I] Test Compound :

(1) N-[(2-hydroxy-2-phenyl)ethyl]-3-{[(1S,2R)-2-(4,5-diphenyloxazol-2-yl)-1-cyclopentyl]methyl}benzamide

(Example 1-47)

(2) N-(2,2-diphenylethyl)-3-{[(1S,2R)-2-(4,5-diphenyloxazol-2-yl)-1-cyclopentyl]methyl}benzamide

(Example 1-50)

(3) N-benzyloxy-3-{[(1S)-2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzamide

(Example 2-46)

(4) N-benzylsulfonyl-3-{[(1S)-2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzamide

(Example 2-75)

[II] Test Method :

The membrane fraction was prepared using COS-7 cells transfected prostanoide receptor sobtype (human EP4).

The standard assay mixture contained membrane fraction, [³H]-PGE₂ in final volume of 0.25ml was incubated for 1 hour at 30°C. The reaction was terminated by that the mixture was rapidly filtered through a glass filter (GF/B). Then the filter was washed by 4ml of ice-cold buffer at two times. The radioactivity associated with the filter was measured by liquid scintillation counting.

In the experiment for competition of specific [³H]-PGE₂ was added at a concentration of 10 μ M. The following buffer was used in all reactions.

Buffer: 20mM Mes (pH 6.0), 1mM EDTA, 10mM MgCl₂

The inhibition (%) of each compound at a concentration of 10 μ M was shown in Table.


[III] Test Result :

Test Compound (1.0 × 10 ⁻⁷ M)	Inhibition (%)
(1)	≥ 80
(2)	≥ 80
(3)	≥ 80
(4)	≥ 80

Methods of mesangial proliferative glomerulonephritis model

Female Wistar rats, 6 weeks old were purchased from SLC (Shizuoka, Japan). Glomerulosclerosis model was produced by intravenous injections (i.v.) of the monoclonal antibody (mAb),

MRC OX-7 (Dainippon Co. Ltd., Osaka, Japan). The 8 weeks old rats were divided into 4 groups (10 rats/group). Group 1 was injected saline instead of OX-7 as a normal group and treated with vehicle (0.5% methylcellulose solution) only. Group 2 was also treated with the vehicle only after the injection of 1mg/kg OX-7 as a control group. Group 3 and Group 4 were treated with N-benzylsulfonyl-3-{[(1S)-2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzamide (Example 2-75), as shown in the following Table. The compound was orally given every day from 5 days before to one day after i.v. administration of the antibody. Urine was collected for 24 hours from the rats in metabolic cages 1 day after injection of OX-7 and the amount of protein in each sample was determined by the biuret method using bovine serum albumine as the standard. All the rats were sacrificed 2 days after injection of OX-7. Blood biochemical analysis was carried out.



Group	Urinary Protein (mg/day)
Normal	40.8 \pm 2.3
Control	127.9 \pm 12.6
Example 2-75 (1mg/kg)	98.2 \pm 20.9
Example 2-75 (10mg/kg)	66.4 \pm 6.9

The pharmaceutical composition of the present invention can be used in the form of a pharmaceutical preparation, for example, in solid, semisolid or liquid form (e.g., tablet, pellet, troche, capsule, suppository, cream, ointment, aerosol, powder, solution, emulsion, suspension etc.), which contains the object compound (I) or a pharmaceutically acceptable salt thereof as an active ingredient, suitable for rectal, pulmonary (nasal or buccal inhalation), nasal, ocular, external (topical), oral or parenteral (including subcutaneous, intravenous and intramuscular) administrations or insufflation.

The pharmaceutical composition of this invention can contain various organic or inorganic carrier materials, which are conventionally used for pharmaceutical purpose, such as excipient (e.g., sucrose, starch, mannitol, sorbitol, lactose, glucose, cellulose, talc, calcium phosphate, calcium carbonate, etc.), binding agent (e.g., cellulose, methyl cellulose, hydroxypropylcellulose, polypropylpyrrolidone, gelatin, gum arabic, polyethyleneglycol, sucrose, starch, etc.), disintegrator (e.g., starch, carboxymethyl cellulose, calcium salt of carboxymethyl cellulose, hydroxypropylstarch, sodium glycol-starch, sodium bicarbonate, calcium phosphate, calcium citrate, etc.), lubricant (e.g., magnesium stearate, talc, sodium laurylsulfate, etc.), flavoring agent (e.g., citric acid, mentol,

glycine, orange powders, etc.), preservative (e.g., sodium benzoate, sodium bisulfite, methylparaben, propylparaben, etc.), stabilizer (e.g., citric acid, sodium citrate, acetic acid, etc.), suspending agent (e.g., methyl cellulose, polyvinylpyrrolidone, aluminum stearate, etc.), dispersing agent, aqueous diluting agent (e.g., water), base wax (e.g., cacao butter, polyethyleneglycol, white petrolatum, etc.).

The effective ingredient may usually be administered with a unit dose of 0.01mg/kg to 50mg/kg, 1 to 4 times a day. However, the above dosage may be increased or decreased according to age, weight, conditions of the patient or the administering method.

The patents, patent applications and publications cited herein are incorporated by reference.

Abbreviations used in this application are as follows :

EtOAc	:	Ethyl acetate
DMF	:	N,N-Dimethylformamide
MeOH	:	Methyl alcohol
NMP	:	N-Methylpyrrolidinone
DMSO	:	Dimethylsulfoxide

The following Preparations and Examples are given only for the purpose of illustrating the present invention in more detail.

Preparation 1

To a solution of 1-cyclohexene-1-carboxylic acid (100g)

in methylene chloride (800ml) was added sulfinyl chloride (117ml) at room temperature. After stirring the mixture for 4 hours, the solvent was evaporated in vacuo. The residue was diluted with methylene chloride (1L) and benzoin (170g) and triethylamine (166ml), and dimethylaminopyridine (10 g) were added to the solution at 0°C under N₂. After stirring the mixture for 4 hours at room temperature, the solvent was evaporated in vacuo, and the residue was partitioned between EtOAc and water. The organic layer was washed with 1N-hydrochloric acid solution, saturated sodium hydrogencarbonate, and brine, dried over magnesium sulfate, and evaporated in vacuo. The obtained compound and ammonium acetate (200g) were dissolved in acetic acid (1500ml) and the mixture was stirred for 4 hours at 100°C. After the solvent was removed, the residue was partitioned between EtOAc and water. The organic layer was washed with water, saturated sodium hydrogencarbonate and brine. The dried solvent was evaporated in vacuo and the residue was purified by chromatography on silica gel to give 1-(4,5-diphenyloxazol-2-yl)-1-cyclohexene (171g).

¹H-NMR (CDCl₃, δ) : 1.6-1.9 (4H, m), 2.2-2.4 (2H, m),
2.5-2.7 (2H, m), 6.90 (1H, m), 7.2-7.8 (10H, m)

MS (m/z) : 302(M+H)⁺

Preparation 2

A solution of AD-mix-α (30g) in a mixture of t-butanol (600ml) and water (600ml) was stirred for 1 hour, and then methanesulfonamide (9.3g) and 1-(4,5-diphenyloxazol-2-yl)-1-cyclohexene added to the solution at room temperature. After

stirring the mixture for 20 hours at the same temperature, sodium sulfite (60g) was added, and the mixture was stirred for 30 minutes. The mixture was partitioned between EtOAc and water. The organic layer was washed with 1N-hydrochloric acid solution, saturated sodium hydrogencarbonate and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by chromatography on silica gel to afford (1R,2S)-1,2-dihydroxy-1-(4,5-diphenyloxazol-2-yl)cyclohexane (30 g).

IR (neat, cm^{-1}) : 3400, 3200, 1460

$^1\text{H-NMR}$ (CDCl_3 , δ) : 1.2-1.9 (7H, m), 2.2-2.4 (1H, m), 3.34 (1H, s), 3.70 (1H, br s), 4.1-4.4 (1H, m), 7.2-7.8 (10H, m)

MS (m/z) : 365 ($\text{M}+\text{H}$) $^+$

Preparation 3

To a solution of (1R,2S)-1,2-dihydroxy-1-(4,5-diphenyloxazol-2-yl)cyclohexane (18g) in methylene chloride (200ml) were added orthoacetic acid trimethyl ester (9.7ml) and p-toluenesulfonic acid (20mg) at room temperature under N_2 . After stirring the mixture for 30 minutes, the solvent was evaporated in vacuo. The residue was diluted with methylene chloride (200ml) and acetyl bromide (5.8ml) was added to the solution at 0°C under N_2 . After stirring the mixture for 2 hours at room temperature, the solvent was evaporated in vacuo, the residue was diluted with MeOH (200ml), and potassium carbonate (12g) was added to the solution at room temperature. The mixture was stirred for 2 hours at the same temperature and partitioned between EtOAc and water. The organic layer was washed with 1N-hydrochloric acid, water, saturated sodium

hydrogencarbonate and brine. The dried solvent was evaporated in vacuo and the residue was purified by chromatography on silica gel to give (1R,2S)-1-(4,5-diphenyloxazol-2-yl)-1,2-epoxycyclohexane (14.1g).

$^1\text{H-NMR}$ (CDCl_3 , δ) : 1.2-1.8 (4H, m), 1.9-2.2 (2H, m),
2.2-2.4 (1H, m), 2.6-2.8 (1H, m), 3.83 (1H, m),
7.2-7.6 (10H, m)

MS (m/z) : 318 (M+H) $^+$

Preparation 4

To a solution of (1R,2S)-1-(4,5-diphenyloxazol-2-yl)-1,2-epoxycyclohexane (20g) and copper bromide (3.0g) in tetrahydrofuran (400ml) was dropwise added a solution of 3-methoxybenzylmagnesium chloride [prepared from 3-methoxybenzylchloride (50g) and Mg (9.2g)] in tetrahydrofuran (500ml) at -78°C under N_2 . The mixture was stirred for 2 hours at the room temperature and partitioned between EtoAc and water. The organic layer was washed with 1N-hydrochloric acid, water, saturated sodium hydrogencarbonate and brine. The dried solvent was evaporated in vacuo and the residue was purified by chromatography on silica gel to give (1R,2S)-1-(4,5-diphenyloxazol-2-yl)-1-hydroxy-2-(3-methoxybenzyl)cyclohexane (29.2g).

IR (Nujol, cm^{-1}): 3400, 1600

$^1\text{H-NMR}$ (CDCl_3 , δ) : 1.4-2.4 (9H, m), 3.07 (1H, d,
 $J=10\text{Hz}$), 3.52 (1H, m), 3.74 (3H, s), 6.7-6.9 (4H,
m), 7.15 (1H, t, $J=8\text{Hz}$), 7.2-7.8 (10H, m)

MS (m/z) : 440 (M+H) $^+$

Preparation 5

A mixture of (1R,2S)-1-(4,5-diphenyloxazol-2-yl)-1-hydroxy-2-(3-methoxybenzyl)cyclohexane (28g) and p-toluene-sulfonic acid (2.5g) in toluene (300ml) was stirred for 4 hours under reflux. The solution was washed with water, saturated sodium hydrogencarbonate and brine, dried over magnesium sulfate and evaporated in vacuo. The residue was purified by chromatography on silica gel to afford (S)-2-(4,5-diphenyloxazol-2-yl)-1-(3-methoxybenzyl)-2-cyclohexene (16g).

$^1\text{H-NMR}$ (CDCl_3 , δ) : 1.4-1.9 (4H, m), 2.1-2.4 (2H, m), 2.53 (1H, dd, $J=10.2, 12.8\text{Hz}$), 3.1-3.3 (1H, m), 3.31 (1H, dd, $J=3.2, 12.8\text{Hz}$), 3.77 (3H, s), 6.80 (1H, 8Hz), 6.9-7.0 (3H, m), 7.20 (1H, t, $J=8\text{Hz}$), 7.2-7.8 (10H, m)

MS (m/z) : 422 ($\text{M}+\text{H}$) $^+$

Preparation 6

To a solution of (S)-2-(4,5-diphenyloxazol-2-yl)-1-(3-methoxybenzyl)-2-cyclohexene (8.5g) in methylene chloride (100 ml) was added boron tribromide (50ml, 1M solution in methylene chloride) at 0°C . After stirring the mixture for 2 hours, the solvent was evaporated in vacuo. The residue was diluted with EtOAc, and the mixture was washed with water and brine. The dried solvent was evaporated in vacuo and dissolved in methylene chloride (50ml). To the solution were added trifluoromethanesulfonic acid anhydride (5.0ml) and 2,6-lutidine (6.2ml) at -78°C . After stirring the mixture for 2 hours,

the solvent was evaporated in vacuo. The residue was diluted with EtOAc, and the mixture was washed with water, saturated sodium hydrogencarbonate and brine. The dried solvent was evaporated in vacuo and the residue was purified by chromatography on silica gel to give (S)-3-{{2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl}methyl}phenyl-trifluoromethanesulfonate (9.1g).

IR (Nujol, cm^{-1}) : 1600, 1520, 1480

$^1\text{H-NMR}$ (CDCl_3 , δ) : 1.4-2.0 (4H, m), 2.2-2.4 (2H, m),
2.60 (1H, dd, $J=10.4$, 13.2Hz), 3.0-3.2 (1H, m),
3.35 (1H, dd, $J=4.0$, 13.2Hz), 6.9 (1H, m), 7.1-7.8
(14H, m)

MS (m/z) : 540 ($M+H$) $^+$

Preparation 7

To a solution of (S)-3-{{2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl}methyl}phenyl trifluoromethanesulfonate (7g) in a mixture of MeOH (30ml) and DMF (40ml) were added 1,3-bis(diphenylphosphino)propane (1.1mg), palladium acetate (0.58mg), and triethylamine (5.4ml). After stirring the mixture for 5 hours at 80°C under CO atmosphere, the resultant mixture was partitioned between EtOAc and water and the organic layer was washed with 1N-hydrochloric acid, saturated sodium hydrogencarbonate, and brine. The dried solvent was evaporated in vacuo and the obtained solid was washed with ether to afford methyl (S)-3-{{2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl}methyl}benzoate (4.2g).

IR (Nujol, cm^{-1}) : 1720

¹H-NMR (CDCl₃, δ) : 1.4-2.0 (4H, m), 2.1-2.4 (2H, m),
2.62 (1H, dd, J=10.0, 13.0Hz), 3.16 (1H, m), 3.33
(1H, dd, J=3.0, 13.0Hz), 3.88 (3H, s), 6.92 (1H, t,
J=4.0Hz), 7.3-7.8 (12H, m), 7.85 (1H, d, J=8Hz),
8.00 (1H, s)
MS (m/z) : 450 (M+H)⁺

Preparation 8

To a solution of methyl (S)-3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzoate (0.3g) in a mixture of ethanol (8ml) and tetrahydrofuran (5ml) was added 1N-sodium hydroxide solution (3.5ml). After stirring the mixture for 24 hours at the same temperature, the solvent was removed. The residue was partitioned between EtOAc and 1N-hydrochloric acid, and the organic layer was washed with brine. The dried solvent was evaporated in vacuo and the obtained solid was washed with a mixture hexane and ether to afford (S)-3-{[2-(4,5-diphenyl-oxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzoic acid (0.28g).

IR (Nujol, cm⁻¹) : 1700

¹H-NMR (CDCl₃, δ) : 1.4-1.9 (4H, m), 2.2-2.4 (2H, m),
2.65 (1H, dd, J=10.0, 13.0Hz), 3.2 (1H, m), 3.35
(1H, dd, J=3.0, 13.0Hz), 6.93 (1H, t, J=3.8Hz),
7.2-7.8 (12H, m), 7.93 (1H, d, J=8Hz), 8.10 (1H, s)
MS (m/z) : 436 (M+H)⁺

Preparation 9

The following compounds described in (1) to (3) were prepared according to a similar manner to those of Preparations

6, 7 and 8.

- (1) 3-{[(1S,2R)-2-(4,5-diphenyloxazol-2-yl)-1-cyclopentyl]-methyl}benzoic acid

IR (Nujol, cm^{-1}) : 1680

$^1\text{H-NMR}$ (CDCl_3 , δ) : 1.4-2.5 (6H, m), 2.5-3.1 (4H, m),
7.2-7.8 (12H, m), 7.82 (1H, d, $J=8\text{Hz}$), 7.93 (1H, s)

MS (m/z) : 424 ($\text{M}+\text{H}$) $^+$

- (2) 3-{[(1SR,2RS)-2-(4,5-diphenyloxazol-2-yl)-1-cyclopentyl]methyl}benzoic acid

$^1\text{H-NMR}$ (CDCl_3 , δ) : 1.4-2.5 (6H, m), 2.5-3.1 (4H, m),
7.2-7.8 (12H, m), 7.82 (1H, d, $J=8\text{Hz}$), 7.93 (1H, s)

MS (m/z) : 424 ($\text{M}+\text{H}$)


- (3) 3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]-methyl}benzoic acid

$^1\text{H-NMR}$ (CDCl_3 , δ) : 1.4-1.9 (4H, m), 2.2-2.4 (2H, m),
2.65 (1H, dd, $J=10.0, 13.0\text{Hz}$), 3.2 (1H, m), 3.35
(1H, dd, $J=3.0, 13.0\text{Hz}$), 6.93 (1H, t, $J=3.8\text{Hz}$),
7.2-7.8 (12H, m), 7.93 (1H, d, $J=8\text{Hz}$), 8.10 (1H, s)

MS (m/z) : 436 ($\text{M}+\text{H}$) $^+$

Examples 1-1 to 1-71

The following compound (Ia) was obtained according to the following Examples 1-1 to 1-71.




















wherein R³ and R⁴ are as defined as the following Table









1.









Concerning each Example, the formula $\begin{array}{c} \text{-N-R}^3 \\ \quad \quad \quad \diagdown \\ \quad \quad \quad \text{R}^4 \end{array}$ in the compound (Ia) and its MS spectrum were shown in Table 1.








Table 1









Example No.	$\begin{array}{c} \text{---N---R}^3 \\ \\ \text{R}^4 \end{array}$	MS(m/z)
1-1		519 (M+H) ⁺
1-2		534 (M+H) ⁺
1-3		505 (M+H) ⁺
1-4		481 (M+H) ⁺
1-5		596 (M+H) ⁺
1-6		564 (M+H) ⁺
1-7		568 (M+H) ⁺
1-8		491 (M+H) ⁺








1-9		589 (M+H) ⁺
1-10		513 (M+H) ⁺
1-11		479 (M+H) ⁺
1-12		463 (M+H) ⁺
1-13		467 (M+H) ⁺
1-14		481 (M+H) ⁺
1-15		511 (M+H) ⁺
1-16		506 (M+H) ⁺
1-17		506 (M+H) ⁺








1-18		499 (M+H) ⁺
1-19		507 (M+H) ⁺
1-20		534 (M+H) ⁺
1-21		525 (M+H) ⁺
1-22		506 (M+H) ⁺
1-23		534 (M+H) ⁺
1-24		507 (M+H) ⁺
1-25		539 (M+H) ⁺








1-26	 <chem>CN1CCCCC1Cc2ccccc2</chem>	591 (M+H) ⁺
1-27	 <chem>CN1CCCCC1C(=O)Oc2ccccc2</chem>	505 (M+H) ⁺
1-28	 <chem>CN(CCCc1ccccc1)CC(C)C</chem>	569 (M+H) ⁺
1-29	 <chem>CN(C)c1ccncc1</chem>	500 (M+H) ⁺
1-30	 <chem>CN(C)CC(C)(C)N</chem>	494 (M+H) ⁺
1-31	 <chem>CN(C)c1ccc(Oc2ccccc2)cc1</chem>	591 (M+H) ⁺
1-32	 <chem>CN(C)c1ccc2c(c1)c[nH]2</chem>	539 (M+H) ⁺
1-33	 <chem>CC(=O)Nc1ccc(NC(C)C)cc1</chem>	556 (M+H) ⁺




1-34		508 (M+H) ⁺
1-35		542 (M+H) ⁺
1-36		521 (M+H) ⁺
1-37		451 (M+H) ⁺
1-38		480 (M+H) ⁺
1-39		541 (M+H) ⁺
1-40		557 (M+H) ⁺

1-41	 <chem>CN1CCCC1C(C)O</chem>	481 (M+H) ⁺
1-42	 <chem>CN1CCCC1C(C)CO</chem>	481 (M+H) ⁺
1-43	 <chem>CN1CCCC1CCCO</chem>	481 (M+H) ⁺
1-44	 <chem>CN(C)C(O)C1CCCC1</chem>	453 (M+H) ⁺
1-45	 <chem>CN1CCCC1CCc2ccccc2</chem>	527 (M+H) ⁺
1-46	 <chem>CN1CCCC1CCCc2ccccc2</chem>	541 (M+H) ⁺
1-47	 <chem>CN1CCCC1C(O)(Cc2ccccc2)C</chem>	543 (M+H) ⁺
1-48	 <chem>CN1CCCC1[C@H](Cc2ccccc2)CO</chem>	557 (M+H) ⁺

1-49		493 (M+H) ⁺
1-50		603 (M+H) ⁺
1-51		507 (M+H) ⁺
1-52		529 (M+H) ⁺
1-53		591 (M+H) ⁺
1-54		542 (M+H) ⁺
1-55		563 (M+H) ⁺

1-56	 <chem>C1CCN(CC1C(O)Cc2ccccc2)C</chem>	597 (M+H) ⁺
1-57	 <chem>CN(C)CC</chem>	494 (M+H) ⁺
1-58	 <chem>CNCCCCc1ccccc1</chem>	555 (M+H) ⁺
1-59	 <chem>CN(Cc1ccccc1)Cc2ccccc2</chem>	603 (M+H) ⁺
1-60	 <chem>CN(C)CCc1ccccn1</chem>	528 (M+H) ⁺
1-61	 <chem>CN(C)CCc1ccncc1</chem>	528 (M+H) ⁺
1-62	 <chem>CN(C)CCc1cccnc1</chem>	528 (M+H) ⁺

1-63	 <chem>CN(C)CCCC1CCCN1</chem>	493 (M+H) ⁺
1-64	 <chem>C1CCCN1CCCC2=CC=CS2</chem>	533 (M+H) ⁺
1-65	 <chem>C1CCCN1CCCC2=CNC3=CC=CC=C23</chem>	566 (M+H) ⁺
1-66	 <chem>CC(C)CCN(C)CCCC1CCCN1</chem>	535 (M+H) ⁺
1-67	 <chem>CN1CCCC1CCCCO</chem>	493 (M+H) ⁺
1-68	 <chem>C1CCCN1CCCC2=CCCCC2</chem>	531 (M+H) ⁺
1-69	 <chem>CN(C)CCCC2=CNC3=CC=CC=C23</chem>	592 (M+H) ⁺

1-70		439 (M+H) ⁺
1-71		453 (M+H) ⁺
1-72		543 (M+H) ⁺

Examples 1-1 to 1-44 and 1-56 to 1-71Coupling of 3-{[(1SR,2RS)-2-(4,5-diphenyloxazol-2-yl)-1-cyclopentyl]methyl}benzoic acid with n different type of amines (n=60)

To a solution of 3-{[(1SR,2RS)-2-(4,5-diphenyloxazol-2-yl)-1-cyclopentyl]methyl}benzoic acid ($n \times 0.01\text{mmol}$) and 2-(1H-benzotrioxazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU) ($n \times 0.015\text{mmol}$) in DMF ($n \times 20 \mu\text{l}$) was added a 1M DMF solution of diisopropylethylamine ($n \times 14 \mu\text{l}$), and the mixture was stirred at 27-30°C for 1 hour. This activated acid solution was then distributed equally into n reaction vessels and to each reaction vessel was added 1M DMF or NMP solution of an amine [$14 \mu\text{l}$, n different type of amines ($n=60$)] and stirred at 27-30°C for 2 hours.

To each reaction mixture was added 5% sodium hydrogencarbonate solution (0.40ml), following by extraction with EtOAc (0.35ml). The resultant aqueous layer was further extracted with EtOAc (0.20ml \times 2). The combined organic layer was washed with water (0.30ml). Then the resultant aqueous layer was additionally extracted with EtOAc (0.20ml \times 2). The combined organic layer was concentrated by nitrogen flow and the resultant residue was dissolved in DMSO (1.0ml) to give a ca. 10^{-2}M DMSO solution of the above compound (Ia) which was subjected to analysis by MS spectrum.

Example 1-45

To a mixture of 3-{[(1S,2R)-2-(4,5-diphenyloxazol-2-yl)-1-cyclopentyl]methyl}benzoic acid (140mg, 0.331mmol) and 2-phenylethylamine (0.046ml, 0.364mmol) in DMF (5ml) was added 1-hydroxybenzotrioxazole (49mg, 0.364mmol) and 1-

ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (95mg, 0.495mmol). After stirring the mixture at room temperature for 2.5 hours, the reaction mixture was diluted with EtOAc (30ml), washed with water, saturated sodium hydrogencarbonate solution, water, and brine. The resultant mixture was dried over magnesium sulfate, and evaporated in vacuo. The resultant residue was purified by silica gel column chromatography (hexane:EtOAc, 2:1 elution) to give N-(2-phenylethyl)-3-{[(1S,2R)-2-(4,5-diphenyloxazol-2-yl)-1-cyclopentyl]methyl}benzamide (172.1mg, 99%).

IR (KBr, cm^{-1}) : 3307, 3059, 3026, 2941, 2870, 1639, 1533, 1446, 1300

$^1\text{H-NMR}$ (CDCl_3 , δ) : 1.35-1.55 (1H, m), 1.67- 2.30 (6H, m), 2.50-3.05 (6H, m), 3.35-3.65 (2H, m), 5.94-6.08 (1H, m), 7.13-7.62 (19H, m)

MS (m/z) : 527 (M+H) $^+$

Example 1-46

The following compound was obtained in a similar manner to that of Example 1-45.

N-(3-phenylpropyl)-3-{[(1S,2R)-2-(4,5-diphenyloxazol-2-yl)-1-cyclopentyl]methyl}benzamide

IR (KBr, cm^{-1}) : 3307, 3057, 3026, 2937, 2866, 1637, 1535, 1444, 1298

$^1\text{H-NMR}$ (CDCl_3 , δ) : 1.35-1.55 (1H, m), 1.68- 2.30 (7H, m), 2.57-3.40 (8H, m), 5.93-6.08 (1H, m), 7.13-7.60 (19H, m)

MS (m/z) : 541 (M + H) $^+$

Example 1-47

The following compound was obtained in a similar manner to that of Example 1-45.

N-[(2-hydroxy-2-phenyl)ethyl]-3-{[(1S,2R)-2-(4,5-diphenyloxazol-2-yl)-1-cyclopentyl]methyl}benzamide

IR (KBr, cm^{-1}) : 3344, 3059, 3030, 2925, 2870, 1641, 1531, 1446, 1298

$^1\text{H-NMR}$ (CDCl_3 , δ) : 1.33-1.55 (1H, m), 1.65-2.30 (5H, m), 2.55-3.03 (4H, m), 3.20-3.42 (1H, m), 3.57-3.78 (2H, m), 4.72-4.88 (1H, m), 6.52-6.70 (1H, m), 7.15-7.58 (19H, m)

MS (m/z) : 543 ($\text{M}+\text{H}$) $^+$

Example 1-48

The following compound was obtained in a similar manner to that of Example 1-45.

N-[(1S)-(1-hydroxymethyl-2-phenyl)ethyl]-3-{[(1S,2R)-2-(4,5-diphenyloxazol-2-yl)-1-cyclopentyl]methyl}benzamide

IR (KBr, cm^{-1}) : 3330, 3059, 3028, 2925, 2868, 1639, 1533, 1446, 1294

$^1\text{H-NMR}$ (CDCl_3 , δ) : 1.33-1.55 (1H, m), 1.65-2.30 (5H, m), 2.50-3.15 (6H, m), 3.42-3.70 (2H, m), 4.10-4.30 (1H, m), 6.36 (1H, d, $J=7.4\text{Hz}$), 7.12-7.60 (19H, m)

MS (m/z) : 557 ($\text{M}+\text{H}$) $^+$

Example 1-49

The following compound was obtained in a similar manner to that of Example 1-45.

4-{3-{[(1S,2R)-2-(4,5-diphenyloxazol-2-yl)-1-cyclopentyl]methyl}benzoyl}morpholine

IR (KBr, cm^{-1}) : 3055, 2956, 2920, 2854, 1635, 1442, 1417, 1277, 1113

$^1\text{H-NMR}$ (CDCl_3 , δ) : 1.33-1.55 (1H, m), 1.65-2.32 (5H, m), 2.53-2.78 (2H, m), 2.83-3.07 (2H, m), 3.10-3.90 (8H, m), 7.10-7.45 (10H, m), 7.45-7.68 (4H, m)

MS (m/z) : 493 ($\text{M}+\text{H}$) $^+$

Example 1-50

The following compound was obtained in a similar manner to that of Example 1-45.

N-(2,2-diphenylethyl)-3-{[(1S,2R)-2-(4,5-diphenyloxazol-2-yl)-1-cyclopentyl]methyl}benzamide

IR (KBr, cm^{-1}) : 3307, 3057, 3028, 2951, 2870, 1641, 1533, 1446, 1294

$^1\text{H-NMR}$ (CDCl_3 , δ) : 1.33-1.53 (1H, m), 1.68-2.30 (5H, m), 2.48-3.02 (4H, m), 3.75-4.05 (2H, m), 4.21 (1H, t, $J=7.8\text{Hz}$), 5.87-6.02 (1H, m), 7.13-7.63 (24H, m)

MS (m/z) : 603 ($\text{M}+\text{H}$) $^+$

Example 1-51

The following compound was obtained in a similar manner to that of Example 1-45.

N,N-di-n-propyl-3-{[(1S,2R)-2-(4,5-diphenyloxazol-2-yl)-1-cyclopentyl]methyl}benzamide

IR (neat, cm^{-1}) : 3057, 2962, 2873, 1631, 1566, 1446, 1379, 1302, 1217

^1H -NMR (CDCl_3 , δ) : 0.58-1.10 (6H, m), 1.25-1.98 (8H, m), 1.98-2.30 (2H, m), 2.50-2.75 (2H, m), 2.90-3.20 (4H, m), 3.25-3.55 (2H, m), 7.10-7.42 (10H, m), 7.50-7.70 (4H, m)

MS (m/z) : 507 ($\text{M}+\text{H}$) $^+$

Example 1-52

To a mixture of 3-{[(1S,2R)-2-(4,5-diphenyloxazol-2-yl)-1-cyclopentyl]methyl}benzoic acid (140mg, 0.331mmol), o-benzylhydroxylamine hydrochloride (69mg, 0.430mmol) and diisopropylethylamine (0.075ml, 0.430mmol) in DMF (5ml) was added 1-hydroxybenzotrioxazole (67mg, 0.497mmol) and 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (127mg, 0.662mmol). After stirring the mixture at room temperature for 2 hours, the reaction mixture was diluted with EtOAc (30ml), washed with 1N hydrochloric acid, water, saturated sodium hydrogencarbonate solution, water, and brine. The resultant mixture was dried over magnesium sulfate, and evaporated in vacuo. The resultant residue was purified by silica gel column chromatography (hexane:EtOAc, 2:1 elution) to give N-benzyloxy-3-{[(1S,2R)-2-(4,5-diphenyloxazol-2-yl)-1-cyclopentyl]methyl}benzamide (170.5mg, 98%).

IR (KBr, cm^{-1}) : 3194, 3059, 3030, 2951, 2870, 1651, 1583, 1502, 1479, 1446, 1294

$^1\text{H-NMR}$ (CDCl_3 , δ) : 1.36-1.55 (1H, m), 1.70- 2.30 (5H, m), 2.57-3.02 (4H, m), 4.87 (1H, d, $J=11.3\text{Hz}$), 4.93 (1H, d, $J=11.3\text{Hz}$), 7.14-7.60 (19H, m), 8.56 (1H, s)
MS (m/z) : 529 ($\text{M}+\text{H}$) $^+$

Example 1-53

To a mixture of 3- $\{[(1\text{S},2\text{R})\text{-}2\text{-(}4,5\text{-diphenyloxazol-}2\text{-yl)-}1\text{-cyclopentyl]methyl}\}$ benzoic acid (120mg, 0.284mmol) and 2-aminodiphenyl ether (68ml, 0.369mmol) in DMF (5ml) was added 1-hydroxybenzotrioxazole (58mg, 0.426mmol), 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (109mg, 0.568mmol), and 4-dimethylaminopyridine (27mg, 0.284mmol). After stirring the mixture at room temperature for 2 hours, the reaction mixture was heated at 80°C for 3 hours. Then, the resultant mixture was diluted with EtOAc (30ml), washed with 1N hydrochloric acid, water, saturated sodium hydrogencarbonate solution, water, and brine. The resultant mixture was dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography (hexane:EtOAc, 4:1 elution) to give N-(2-phenoxyphenyl)-3- $\{[(1\text{S},2\text{R})\text{-}2\text{-(}4,5\text{-diphenyloxazol-}2\text{-yl)-}1\text{-cyclopentyl]methyl}\}$ benzamide (84.7mg, 51%).

IR (neat, cm^{-1}) : 3060, 2954, 2870, 1680, 1603, 1587, 1523, 1487, 1446

$^1\text{H-NMR}$ (CDCl_3 , δ) : 1.35-1.55 (1H, m), 1.70- 2.30 (5H, m), 2.54-3.05 (4H, m), 6.80-7.62 (22H, m), 8.36 (1H, s), 8.55 (1H, dd, $J=8.0, 1.6\text{Hz}$)

MS (m/z) : 591 ($\text{M}+\text{H}$) $^+$

Example 1-54

To a mixture of 3-{[(1S,2R)-2-(4,5-diphenyloxazol-2-yl)-1-cyclopentyl]methyl}benzoic acid (120mg, 0.284mmol) and 2-(2-methylaminoethyl)pyridine (0.047ml, 0.341mmol) in DMF (5ml) was added 1-hydroxybenzotrioxazole (58mg, 0.426mmol) and 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (109mg, 0.568mmol). After stirring the mixture at room temperature for 2 hours, the reaction mixture was diluted with EtOAc (30ml), washed with water, saturated sodium hydrogencarbonate solution, water, and brine. The resultant mixture was dried over magnesium sulfate, and evaporated in vacuo. The resultant residue was purified by silica gel column chromatography (methylene chloride: MeOH, 15:1 elution), then treated with 4N hydrogen chloride in EtOAc (1ml) to give N-methyl-N-[2-(pyridin-2-yl)ethyl]-3-{[(1S,2R)-2-(4,5-diphenyloxazol-2-yl)-1-cyclopentyl]methyl}benzamide (140.9mg, 86%).

IR (KBr, cm^{-1}) : 3408, 3053, 2945, 2870, 2603, 1630, 1498, 1469, 1444, 1402

$^1\text{H-NMR}$ (DMSO-d_6 , δ) : 1.30-1.52 (1H, m), 1.62- 2.27 (5H, m), 2.40-3.10 (6H, m), 3.20-3.40 (3H, m), 3.70-3.92 (2H, m), 6.80-7.58 (14H, m), 7.75-8.08 (2H, m), 8.30-8.55 (1H, m), 8.65-8.85 (1H, m)

MS (m/z) : 542 $[(M+H)^+-\text{HCl}]$

Example 1-55

The following compound was obtained in a similar manner to that of Example 1-54.

N-benzenesulfonyl-3-{[(1S,2R)-2-(4,5-diphenyloxazol-2-

yl)-1-cyclopentyl]methyl}benzamide

IR (Nujol, cm^{-1}) : 1690

$^1\text{H-NMR}$ (CDCl_3 , δ) : 1.6- 2.3 (8H, m), 2.5-2.7 (1H, m),
3.1-3.2 (1H, m), 6.94 (1H, m), 7.3-8.2 (19H, m)

MS (m/z) : 563 ($M + H$) $^+$

Example 1-72

To a mixture of 3-{[(1S,2R)-2-(4,5-diphenyloxazol-2-yl)-1-cyclopentyl]methyl}benzoic acid (76mg, 0.18mmol) and (S)-2-amino-1-phenylethanol (30mg, 0.22mmol) in DMF (4ml) was added 1-hydroxybenzotriazole (36mg, 0.27mmol) and 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (69mg, 0.36mmol). After stirring the resulting mixture at room temperature for 2 hours, the reaction mixture was diluted with EtOAc (30ml), washed with 1N-hydrochloric acid, water, saturated sodium hydrogencarbonate solution, water and brine successively, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography (hexane:EtOAc, 1:1 elution) to give N-[(2S)-2-hydroxy-2-phenylethyl]-3-{[(1S,2R)-2-(4,5-diphenyloxazol-2-yl)-1-cyclopentyl]methyl}benzamide (92.8mg, 95%).


IR (KBr, cm^{-1}) : 3334, 3059, 3030, 2933, 2870, 1643, 1537,
1448, 1313

$^1\text{H-NMR}$ (CDCl_3 , δ) : 1.32-1.60 (1H, m), 1.65-2.28 (5H, m), 2.55-3.03 (4H, m), 3.20-3.36 (1H, m), 3.63-3.78 (2H, m), 4.77-4.88 (1H, m), 6.60-6.73 (1H, m), 7.18-7.60 (19H, m)

MS (m/z) : 543 (M+H⁺)

Examples 2-1 to 2-89

The following compound (Ib) was obtained according to the following Examples 2-1 to 2-89.



















(Ib)









wherein R^3 and R^4 are as defined as the following Table 2.









Concerning each Example, the formula $\text{-N}(\text{R}^3)(\text{R}^4)$ in the compound (Ib) and its MS spectrum were shown in Table 2.








Table 2










Example No.	$\begin{array}{c} \text{---N---R}^3 \\ \\ \text{R}^4 \end{array}$	MS(m/z)
2-1		531 (M+H) ⁺
2-2		546 (M+H) ⁺
2-3		517 (M+H) ⁺
2-4		493 (M+H) ⁺
2-5		554 (M+H) ⁺
2-6		608 (M+H) ⁺
2-7		576 (M+H) ⁺









2-8		580 (M+H) ⁺
2-9		601 (M+H) ⁺
2-10		525 (M+H) ⁺
2-11		491 (M+H) ⁺
2-12		475 (M+H) ⁺
2-13		479 (M+H) ⁺
2-14		493 (M+H) ⁺
2-15		523 (M+H) ⁺
2-16		518 (M+H) ⁺







2-17	 <chem>CN(C)[C@H]1CCNC1</chem>	518 (M+H) ⁺
2-18	 <chem>CNc1ccccc1</chem>	511 (M+H) ⁺
2-19	 <chem>CN1CCC[C@H]1CO</chem>	519 (M+H) ⁺
2-20	 <chem>CN(C)C1CCN(CC)CC1</chem>	546 (M+H) ⁺
2-21	 <chem>CN1C=Cc2ccccc2N1</chem>	537 (M+H) ⁺
2-22	 <chem>CN(C)C1CCN(C)CC1</chem>	518 (M+H) ⁺
2-23	 <chem>CN(C)C1CC(=O)NCC1</chem>	546 (M+H) ⁺
2-24	 <chem>CN(C)C1CC(O)CCN1</chem>	519 (M+H) ⁺









2-25		503 (M+H) ⁺
2-26		551 (M+H) ⁺
2-27		593 (M+H) ⁺
2-28		517 (M+H) ⁺
2-29		581 (M+H) ⁺
2-30		505 (M+H) ⁺
2-31		512 (M+H) ⁺
2-32		506 (M+H) ⁺








2-33		603 (M+H) ⁺
2-34		603 (M+H) ⁺
2-35		551 (M+H) ⁺
2-36		519 (M+H) ⁺
2-37		568 (M+H) ⁺
2-38		520 (M+H) ⁺
2-39		554 (M+H) ⁺









2-40		533 (M+H) ⁺
2-41		451 (M+H) ⁺
2-42		465 (M+H) ⁺
2-43		463 (M+H) ⁺
2-44		492 (M+H) ⁺
2-45		465 (M+H) ⁺
2-46		541 (M+H) ⁺
2-47		575 (M+H) ⁺
2-48		633 (M+Na) ⁺





2-49		605 (M+Na) ⁺
2-50		581 (M-Na) ⁻
2-51		631 (M+Na) ⁺
2-52		577 (M+Na) ⁺
2-53		561 (M+Na) ⁺
2-54		515 (M+Na) ⁺
2-55		528 (M+Na) ⁺
2-56		575 (M+Na) ⁺

2-57		589 (M+Na) ⁺
2-58		575 (M+Na) ⁺
2-59		637 (M+Na) ⁺
2-60		637 (M+Na) ⁺
2-61		591 (M+Na) ⁺
2-62		591 (M+Na) ⁺

2-63		562 (M+Na) ⁺
2-64		562 (M+Na) ⁺
2-65		562 (M+Na) ⁺
2-66		515 (M+Na) ⁺
2-67		515 (M+Na) ⁺
2-68		527 (M+Na) ⁺
2-69		567 (M+Na) ⁺
2-70		600 (M+Na) ⁺

2-71		569 (M+Na) ⁺
2-72		527 (M+Na) ⁺
2-73		565 (M+Na) ⁺
2-74		592 (M+H) ⁺
2-75		589 (M+H) ⁺
2-76		521 (M+H) ⁺
2-77		493 (M+H) ⁺

2-78		597 (M+H) ⁺
2-79		583 (M+H) ⁺
2-80		562 (M+Na) ⁺
2-81		540 (M-HCl+H) ⁺
2-82		555 (M+H) ⁺
2-83		641 (M+H) ⁺
2-84		635 (M+H) ⁺
2-85		625 (M+H) ⁺

2-86		597 (M+H) ⁺
2-87		474 (M+H) ⁺
2-88		591 (M+H) ⁺
2-89		511 (M-H) ⁻

Examples 2-1 to 2-45 and 2-51 to 2-74Coupling of (±)-3-[[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl]benzoic acid with n different type of amines (n=69)

To a solution of (±)-3-[[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl]benzoic acid ($n \times 0.01\text{mmol}$) and 2-(1H-benzotrioxazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU) ($n \times 0.015\text{mmol}$) in DMF ($n \times 20\mu\text{l}$) was added a 1M DMF solution of diisopropylethylamine ($n \times 14\mu\text{l}$), and the mixture was stirred at 27-30°C for 1 hour. This activated acid solution was then distributed equally into n reaction vessels. To each reaction vessel was added 1M DMF or NMP solution of an amine [$14\mu\text{l}$, n different type of amines ($n=69$)] and stirred at 27-30°C for 2 hours.

To each reaction mixture was added 5% sodium hydrogencarbonate solution (0.40ml), following by extraction with EtOAc (0.35ml). The resultant aqueous layer was further extracted with EtOAc (0.20ml \times 2). The combined organic layer was washed with water (0.30ml). Then the resultant aqueous layer was additionally extracted with EtOAc (0.20ml \times 2). The combined organic layer was concentrated by nitrogen flow and the resultant residue was dissolved in DMSO (1.0ml) to give a ca. 10^{-2}M DMSO solution of the above compound (Ib) which was subjected to analysis by MS spectrum.

Example 2-46

To a mixture of 3-[[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl]benzoic acid (150mg, 0.345mmol), o-

benzylhydroxylamine hydrochloride (61mg, 0.379mmol) and diisopropylethylamine (0.066ml, 0.379mmol) in DMF (5ml) was added 1-hydroxybenzotrioxazole (52mg, 0.379mmol) and 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (99mg, 0.518mmol). After stirring the mixture at room temperature for 1.5 hours, the reaction mixture was diluted with EtOAc (30ml), washed with water, saturated sodium hydrogencarbonate solution, water, and brine. The resultant mixture was dried over magnesium sulfate, and evaporated in vacuo. The resultant residue was purified by silica gel column chromatography (hexane:EtOAc, 2:1 elution) to give N-benzyloxy-3-{[(1S)-2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzamide (136.8mg, 74%).

IR (KBr, cm^{-1}) : 3251, 3030, 2931, 2858, 1647, 1504, 1444, 1298

$^1\text{H-NMR}$ (CDCl_3 , δ) : 1.40-1.90 (4H, m), 2.20- 2.40 (2H, m), 2.61 (1H, dd, $J=13.0$, 9.8Hz), 3.07-3.25 (1H, m), 3.28 (1H, dd, $J=13.0$, 3.8Hz), 4.98 (2H, s), 6.91 (1H, dd, $J=3.8$, 3.8Hz), 7.22-7.75 (19H, m), 8.55 (1H, s)

MS (m/z) : 541 ($\text{M}+\text{H}$) $^+$

Example 2-47

The following compound was obtained in a similar manner to that of Example 2-46.

N-benzenesulfonyl-3-{[(1S)-2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzamide

IR (Nujol, cm^{-1}) : 1670

$^1\text{H-NMR}$ (CDCl_3 , δ) : 1.4-1.8 (4H, m), 2.2-2.4 (2H, m),

2.59 (1H, dd, J=13.0, 9.8Hz), 3.0-3.3 (2H, m), 6.92
(1H, m), 7.2-8.2 (19H, m)

MS (m/z) : 575 (M + H)⁺

Example 2-48

To a mixture of 3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzoic acid (150mg, 0.345mmol), L-phenylalanine ethyl ester hydrochloride (103mg, 0.448mmol) and diisopropylethylamine (0.078ml, 0.448mmol) in DMF (5ml) was added 1-hydroxybenzotrioxazole (70mg, 0.518mmol) and 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (132mg, 0.690mmol). After stirring the mixture at room temperature for 4 hours, the reaction mixture was diluted with EtOAc (30ml), washed with 1N hydrochloric acid, water, saturated sodium hydrogencarbonate solution, water, and brine. The resultant mixture was dried over magnesium sulfate, and evaporated in vacuo. The resultant residue was purified by silica gel column chromatography (hexane:EtOAc, 3:1 elution) to give ethyl (2S)-2-{3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzoylamino}-3-phenylpropionate (197.1mg, 94%).

IR (KBr, cm⁻¹) : 3309, 2933, 1739, 1645, 1603, 1585, 1531,
1446

¹H-NMR (CDCl₃, δ) : 1.20-1.34 (3H, m), 1.40- 1.90 (4H, m), 2.05-2.50 (2H, m), 2.50-2.70 (1H, m), 3.10-3.43 (4H, m), 4.12-4.28 (2H, m), 4.98-5.10 (1H, m),
6.54-6.65 (1H, m), 6.89-6.97 (1H, m), 7.08-7.77
(19H, m)

MS (m/z) : 633 (M+Na)⁺

Example 2-49

To a solution of ethyl (2S)-2-{3-[[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl]benzoylamino}-3-phenylpropionate (119mg, 0.195mmol) in tetrahydrofuran (4ml) was added a solution of lithium hydroxide-water (16.4mg, 0.390mmol) in MeOH-water (1:1) (2.8ml) at 5°C. The reaction mixture was stirred at the same temperature for 1 hour, and then stirred at room temperature for 30 minutes. To the reaction mixture was added 1N hydrochloric acid (0.5ml) at 5°C and extracted with EtOAc. The organic layer was washed with water and brine. The resultant mixture was dried over magnesium sulfate, and evaporated in vacuo to give (2S)-2-{3-[[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl]benzoylamino}-3-phenylpropionic acid (113.0mg, 100%).

IR (KBr, cm^{-1}) : 3413, 2933, 1732, 1641, 1525, 1446

$^1\text{H-NMR}$ (CDCl_3 , δ) : 1.40-1.95 (4H, m), 2.05-2.50 (2H, m), 2.50-2.73 (1H, m), 3.05-3.40 (4H, m), 4.87-5.03 (1H, m), 6.60-6.85 (1H, m), 6.85-6.98 (1H, m), 7.08-7.75 (19H, m)

MS (m/z) : 605 ($M+\text{Na}$)⁺

Example 2-50

To a solution of (2S)-2-{3-[[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl]benzoylamino}-3-phenylpropionic acid (85.4mg, 0.147mmol) in MeOH (3ml) was added 1N sodium hydroxide (0.147ml, 0.147mmol) at 5°C. The reaction mixture was stirred at the same temperature for 30 minutes, and evaporated in vacuo. To the residue was added ethyl ether, and the resulting solid was collected by filtration to

give sodium (2S)-2-{3-[[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzoylamino}-3-phenylpropionate (84.9mg, 96%).

IR (KBr, cm^{-1}) : 3357, 2931, 2860, 1643, 1601, 1531, 1446, 1400

$^1\text{H-NMR}$ (DMSO-d_6 , δ) : 1.30-1.93 (4H, m), 2.05-2.70 (3H, m), 2.93-3.35 (4H, m), 4.05-4.21 (1H, m), 6.87-6.97 (1H, m), 7.08-7.78 (20H, m)

MS (m/z) : 581 (M-Na)

Example 2-75

To a mixture of 3-[[[(1S)-2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzoic acid (250mg, 0.575mmol) and α -toluenesulfonamide (98mg, 0.575mmol) in DMF (6ml) was added 4-dimethylaminopyridine (105mg, 0.863mmol) and 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (220mg, 1.15mmol). After stirring the resulting mixture at room temperature for 16 hours, the reaction mixture was diluted with EtOAc (30ml), washed with 1N-hydrochloric acid, water and brine successively, dried over dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography (hexane:EtOAc, 1:1 elution) to give N-benzylsulfonyl-3-[[[(1S)-2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzamide (216.4mg, 64%).

IR (KBr, cm^{-1}) : 3244, 3060, 2933, 1693, 1450, 1344, 1155

$^1\text{H-NMR}$ (CDCl_3 , δ) : 1.45-1.90 (4H, m), 2.08-2.50 (2H, m), 2.62 (1H, dd, $J=13.0, 10.1\text{Hz}$), 3.05-3.22 (1H, m), 3.27 (1 H, dd, $J =13.0, 3.6\text{Hz}$), 4.67 (1H, d,

J = 14.0Hz), 4.77 (1H, d, J=14.0Hz), 6.93 (1H, dd, J = 3.9, 3.9Hz), 7.20-7.80 (19H, m), 8.85 (1 H, br)
MS (m/z) : 589 (M+H⁺)

Example 2-76

To a mixture of (±)-3-{{2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl}methyl}benzoic acid (150mg, 0.345mmol), glycine ethyl ester hydrochloride (63mg, 0.449mmol) and diisopropylethylamine (0.078ml, 0.449mmol) in DMF (5ml) was added 1-hydroxybenzotriazole (70mg, 0.518mmol) and 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (132mg, 0.690mmol). After stirring the resulting mixture at room temperature for 3 hours, the reaction mixture was diluted with EtOAc (30ml), washed with 1N-hydrochloric acid, water, saturated sodium hydrogencarbonate solution, water and brine successively, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography (hexane:EtOAc, 2:1 elution) to give ethyl (±)-{3-{{2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl}methyl}-benzoylamino}acetate (168.9mg, 94%).

IR (KBr, cm⁻¹) : 3332, 3055, 2933, 1749, 1649, 1533, 1196

¹H-NMR (CDCl₃, δ) : 1.31 (3H, t, J= 7.1Hz), 1.40-1.90 (4H, m), 2.08-2.45 (2H, m), 2.64 (1H, dd, J=13.0, 9.8Hz), 3.10-3.38 (2H, m), 4.02-4.13 (2H, m), 4.25 (2H, q, J=7.1Hz), 6.53-6.70 (1H, m), 6.88-6.96 (1H, m), 7.18-7.80 (14H, m)

MS (m/z) : 521 (M+H⁺)

Example 2-77

To a solution of ethyl (\pm)-{3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzoylamino}acetate (136.8mg, 0.263mmol) in tetrahydrofuran (4ml) was added a solution of lithium hydroxide-water (22.1mg, 0.526mmol) in MeOH-water (1:1) (2.8ml) at 5°C and the mixture was stirred at room temperature for 2 hours. To the reaction mixture was added 1N-hydrochloric acid (0.8ml) at 5°C and extracted with EtOAc. The organic layer was washed with water and brine successively, dried over magnesium sulfate, and evaporated in vacuo to give (\pm)-{3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzoylamino}acetic acid (129.0mg, 100%).

IR (KBr, cm^{-1}) : 3346, 3055, 2933, 1732, 1645, 1535

$^1\text{H-NMR}$ (CDCl_3 , δ) : 1.50-1.95 (4H, m), 2.10-2.50 (2H, m), 2.68 (1H, dd, $J=14.9, 10.4\text{Hz}$), 3.10-3.30 (2H, m), 3.85-4.30 (2H, m), 6.82-7.00 (2H, m), 7.18-7.75 (14H, m)

MS (m/z) : 493 ($\text{M}+\text{H}^+$)

Preparation 10

To a solution of tyramine (3.0g, 21.9mmol) in tetrahydrofuran (30ml) was added di-tert-butyl dicarbonate (5.26g, 24.1mmol) at 5°C and the mixture was stirred at room temperature for 1 hour. The solvent was removed in vacuo and the residue was diluted with EtOAc, washed with water and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography (hexane:EtOAc, 3:1-2:1 elution) to give tert-butyl [2-(4-hydroxyphenyl)ethyl]carbamate (5.77g, 111%) as an oil.

IR (neat, cm^{-1}) : 3346, 2978, 2933, 1685, 1614, 1514, 1450,

1367

^1H -NMR (CDCl_3 , δ) : 1.44 (9H, s), 2.71 (2H, t, $J=7.0\text{Hz}$), 3.24-3.40 (2H, m), 4.48-4.62 (1H, m), 5.43 (1H, s), 6.77 (2H, d, $J=8.5\text{Hz}$), 7.04 (2H, d, $J=8.5\text{Hz}$)

MS (m/z) : 138 ($\text{M}-\text{C}_5\text{H}_9\text{O}_2+2\text{H}$) $^+$

Preparation 11

To a solution of tert-butyl [2-(4-hydroxyphenyl)-ethyl]carbamate (5.69g, 24.0mmol) and 2,6-lutidine (5.59ml, 48.0mmol) in methylene chloride (85ml) was added trifluoromethanesulfonic anhydride (5.0ml, 29.7mmol) at 5°C and the mixture was stirred for 30 min. The solvent was removed in vacuo and the residue was diluted with EtOAc, washed with 1N-hydrochloric acid, water, saturated sodium hydrogencarbonate solution, water and brine successively, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography (hexane:EtOAc, 5:1) to give 4-[2-(tert-butoxycarbonylamino)-ethyl]phenyl trifluoromethanesulfonate (6.15g, 69%).

IR (KBr, cm^{-1}) : 3383, 2987, 1682, 1527, 1417, 1250

^1H -NMR (CDCl_3 , δ) : 1.43 (9H, s), 2.83 (2H, t, $J=7.0\text{Hz}$), 3.28-3.45 (2H, m), 4.43-4.63 (1H m), 7.14-7.34 (4H, m)

MS (m/z) : 270 ($\text{M}-\text{C}_5\text{H}_9\text{O}_2+2\text{H}$) $^+$

Preparation 12

A mixture of 4-[2-(tert-butoxycarbonylamino)ethyl]-phenyl trifluoromethanesulfonate (6.11g, 16.6mmol), palladium(II) acetate (745mg, 3.32mmol), 1,3-bis-(diphenylphosphino)propane (1.37g, 3.32mmol), triethylamine (6.94ml, 49.8mmol), and MeOH (24ml) in DMF (60ml) was purged for 30 min with carbon monoxide. The mixture was stirred under carbon monoxide atmosphere at 78°C for 3 hours. After cooling the mixture to room temperature, the reaction mixture was diluted with EtOAc, washed with water, 1N-hydrochloric acid, water, saturated sodium hydrogencarbonate, water and brine successively, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography (hexane:EtOAc, 4:1~3:1) to give methyl 4-[2-(tert-butoxycarbonylamino)ethyl]benzoate (3.52g, 76%).

IR (KBr, cm^{-1}) : 3371 , 2978, 2947, 1722, 1680, 1525, 1277

$^1\text{H-NMR}$ (CDCl_3 , δ) : 1.43 (9H, s), 2.86 (2H, t, $J=7.0\text{Hz}$), 3.32-3.45 (2H, m), 3.91 (3H, s), 4.45-4.63 (1H, m), 7.27 (2H, d, $J=8.3\text{ Hz}$), 7.98 (2H, d, $J=8.3\text{ Hz}$)

MS (m/z) : 1 80 ($\text{M}-\text{C}_5\text{H}_9\text{O}_2+2\text{H}$)⁺

Preparation 13

To a solution of methyl 4-[2-(tert-butoxycarbonylamino)ethyl]benzoate (3.50g, 12.5mmol) in methylene chloride (35ml) was added 4N hydrogen chloride in 1,4-dioxane (35ml) at 5°C and the mixture was stirred for 30 min. The solvent was removed in vacuo and the resulting solid was collected, washed

with isopropyl ether and dried to give methyl 4-(2-aminoethyl)-benzoate hydrochloride (2.63g, 97%).

IR (KBr, cm^{-1}) : 2970, 1726, 1606, 1466, 1435, 1281

$^1\text{H-NMR}$ (DMSO-d_6 , δ) : 2.92-3.20 (4H, m), 3.85 (3H, s),
7.43 (2H, d, $J=8.3$ Hz), 7.93 (2H, d, $J=8.3$ Hz), 8.14
(3H, br)

MS (m/z) : 180 ($\text{M-HCl}+\text{H}^+$)

Example 2-78

The following compound was obtained in a similar manner to that of Example 2-76.

methyl (\pm)-4-{2-{3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzoylamino}ethyl}benzoate

IR (KBr, cm^{-1}) : 3329, 2927, 2856, 1716, 1635, 1535, 1444,
1275

$^1\text{H-NMR}$ (DMSO-d_6 , δ) : 1.35-1.90 (4H, m), 2.03-2.50 (2H,
m), 2.50-2.70 (1H, m), 2.93 (2H, t, $J=6.9$ Hz), 2.99-
3.35 (2H, m), 3.40-3.62 (2H, m), 3.82 (3H, s), 6.88
-6.97 (1H, m), 7.30-7.72 (15H, m), 7.75 (1H, s),
7.89 (2H, d, $J=8.2$ Hz), 8.53 (1H, t, $J=5.6$ Hz)

MS (m/z) : 597 ($\text{M}+\text{H}^+$)

Example 2-79

The following compound was obtained in a similar manner to that of Example 2-77.

(\pm)-4-{2-{3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen

-1-yl]-methyl}benzoylamino}ethyl}benzoic acid

IR (KBr, cm^{-1}) : 3319, 2933, 1691, 1635, 1537, 1284

$^1\text{H-NMR}$ (DMSO-d_6 , δ) : 1.35-1.98 (4H, m), 2.05-2.50 (2H, m), 2.50-2.70 (1H, m), 2.80-3.00 (2H, m), 3.00-3.60 (4H, m), 6.88-6.95 (1H, m), 7.28-7.72 (15H, m), 7.76 (1H, s), 7.87 (2H, d, $J=8.2\text{Hz}$), 8.45-8.60 (1H, m)

MS (m/z) : 583 ($M+H^+$)

Example 2-80

To a mixture of (S)-3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzoic acid (120mg, 0.276mmol) and 2-(2-aminoethyl)pyridine (0.040ml, 0.331mmol) in DMF (5ml) was added 1-hydroxybenzotriazole (56mg, 0.414mmol) and 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (106mg, 0.552mmol). After stirring the resulting mixture at room temperature for 2 hours, the reaction mixture was diluted with EtOAc (30ml), washed with water, saturated sodium hydrogencarbonate solution, water and brine successively, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography (methylene chloride:MeOH, 20:1 elution) to give (S)-N-[2-(2-pyridyl)ethyl]-3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzamide (138.8mg, 93%).

$^1\text{H-NMR}$ (CDCl_3 , δ) : 1.40-1.90 (4H, m), 2.10-2.50 (2H, m), 2.62 (1H, dd, $J=13.3, 11.5\text{Hz}$), 3.07 (2H, t, $J=6.3\text{Hz}$), 3.13-3.43 (2H, m), 3.76-3.90 (2H, m), 6.89-6.97 (1H, m), 7.05-7.78 (18H, m), 8.47-8.56

(1H, m)

Example 2-81.

To a solution of (S)-N-[2-(2-pyridyl)ethyl]-3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzamide (130mg, 0.241mmol) in ethyl ether (4ml) was added 4N hydrogen chloride in EtOAc (0.5ml) at room temperature. The solvent was removed in vacuo and the resulting solid was collected, washed with ethyl ether, and dried to give (S)-N-[2-(2-pyridyl)ethyl]-3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzamide hydrochloride (135.2mg, 97%).

IR (KBr, cm^{-1}) : 3292, 3055, 2933, 1645, 1535, 1298,
1066

^1H -NMR (DMSO- d_6 , δ) : 1.35-1.95 (4H, m), 2.05-2.50
(2H, m), 2.55-2.70 (1H, m), 2.98-3.40 (4H, m),
3.60-3.83 (2H, m), 6.88-6.95 (1H, m), 7.25-7.78
(14H, m), 7.80-8.00 (2H, m), 8.39-8.53 (1H, m),
8.58-8.73 (1H, m), 8.73-8.88 (1H, m)

MS (m/z) : 540(M-HCl+H $^+$)

Example 2-82

To a mixture of (\pm)-3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzoic acid (300mg, 0.690mmol) and tyramine (123mg, 0.897mmol) in DMF (5ml) was added 1-hydroxybenzotriazole (140mg, 1.04mmol) and 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (265mg, 1.38mmol). After stirring the resulting mixture at room temperature for 3 hours, the reaction mixture was diluted with EtOAc (30ml), washed with 1N-hydrochloric acid, water,

saturated sodium hydrogencarbonate solution, water and brine successively, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography (hexane:EtOAc, 3:2 elution) to give (\pm)-N-[2-(4-hydroxyphenyl)ethyl]-3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzamide (358.4mg, 94%).

IR (KBr, cm^{-1}) : 3336, 2933, 1633, 1537, 1514, 1444, 1309, 1232

$^1\text{H-NMR}$ (DMSO-d_6 , δ) : 1.38-2.08 (4H, m), 2.08-2.50 (2H, m), 2.50-2.80 (3H, m), 3.00-3.50 (4H, m), 6.68 (2H, d, $J=8.4$ Hz), 6.88-6.98 (1H, m), 7.03 (2H, d, $J=8.4$ Hz), 7.25-7.74 (13H, m), 7.79 (1H, s), 8.49 (1H, t, $J=5.4$ Hz), 9.17 (1H, s)

MS (m/z) : 555 ($M+H^+$)

Example 2-83

To a mixture of (\pm)-N-[2-(4-hydroxyphenyl)ethyl]-3-[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzamide (120mg, 0.217mmol) and potassium carbonate (60mg, 0.434mmol) in DMF (4ml) was added ethyl bromoacetate (0.048ml, 0.435mmol) and stirred at room temperature for 17 hours. The reaction mixture was diluted with EtOAc, washed with water and brine successively, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography (hexane:EtOAc, 3:1~2:1) to give ethyl (\pm)-4-{2-{3-[[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzoylamino}ethyl}phenoxyacetate (130.0mg, 94%).

IR (KBr, cm^{-1}) : 3309, 2931, 1757, 1643, 1535, 1510

$^1\text{H-NMR}$ (CDCl_3 , δ) : 1.29 (3H, t, $J=7.1\text{Hz}$), 1.40-1.95 (4H, m), 2.05-2.45 (2H, m), 2.62 (1H, dd, $J=13.0$, 9.9Hz), 2.80 (2H, t, $J=7.0\text{Hz}$), 3.06-3.25 (1H, m), 3.30 (1H, dd, $J=13.0$, 3.5Hz), 3.47-3.67 (2H, m), 4.26 (2H, q, $J=7.1\text{Hz}$), 4.58 (2H, s), 6.11 (1H, t, $J=6.1\text{Hz}$), 6.85 (2H, d, $J=8.7\text{Hz}$), 6.87-6.97 (1H, m), 7.13 (2H, d, $J=8.7\text{Hz}$), 7.20-7.74 (14H, m)
MS (m/z) : 641 ($\text{M}+\text{H}^+$)

Example 2-84

To a solution of ethyl (\pm)-4-{2-{3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}-benzoylamino}ethyl}phenoxyacetate (115mg, 0.18mmol) in MeOH-1,4-dioxane (1:1, 4ml) was added 1N sodium hydroxide solution (0.18ml, 0.18mmol) at 5°C and the mixture was stirred at room temperature for 2 hours. The reaction mixture was evaporated and Et_2O was added thereto. The resulting solid was collected by filtration to give sodium (\pm)-4-{2-{3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}-benzoylamino}ethyl}phenoxyacetate (105.0mg, 92%).

IR (KBr , cm^{-1}) : 3334, 2929, 1639, 1604, 1512, 1425

$^1\text{H-NMR}$ (DMSO-d_6 , δ) : 1.35-1.95 (4H, m), 2.10-2.83 (5H, m), 3.00-3.50 (4H, m), 4.03 (2H, s), 6.73 (2H, d, $J=8.5\text{Hz}$), 6.85-6.95 (1H, m), 7.08 (2H, d, $J=8.5\text{Hz}$), 7.30-7.73 (13H, m), 7.80 (1H, s), 8.48-8.62 (1H, m)

MS (m/z) : 635 ($\text{M}+\text{H}^+$)

Preparation 14

To a solution of 2-phenylethylamine (3.0g, 24.8mmol) in DMF (30ml) was added ethyl bromoacetate (3.0ml, 27.3mmol) at 5°C. Then triethylamine (4.15ml, 29.8mmol) was added thereto at the same temperature. After stirring the resulting mixture at room temperature for 18 hours, the reaction mixture was diluted with EtOAc, washed with water and brine successively, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography (methylene chloride:MeOH, 20:1) to give ethyl phenethylaminoacetate (1.87g, 37%) as an oil.

IR (neat, cm^{-1}) : 3028, 2935, 1738, 1454, 1201, 1146, 1028

$^1\text{H-NMR}$ (CDCl_3 , δ) : 1.26 (3H, t, $J=7.1\text{Hz}$), 2.74-2.94 (4H, m), 3.41 (2H, s), 4.17 (2H, q, $J=7.1\text{Hz}$), 7.15-7.35 (5H, m)

MS (m/z) : 208 ($\text{M}+\text{H}^+$)

Example 2-85

The following compound was obtained in a similar manner to that of Example 2-82.

Ethyl (\pm) - { 3 - { [2 - (4,5-diphenyloxazol-2-yl) - 2-cyclohexen-1-yl] methyl } benzoyl } - N-phenethylaminoacetate

IR (KBr, cm^{-1}) : 2933, 1745, 1643, 1446, 1200

$^1\text{H-NMR}$ (CDCl_3 , δ) : 1.13-1.38 (3H, m), 1.38-1.90 (4H, m), 2.05-2.45 (2H, m), 2.45-2.63 (1H, m), 2.63-3.08 (2H, m), 3.08-3.43 (2H, m), 3.43-4.35 (6H, m), 6.85-7.00 (2H, m), 7.10-7.55 (14H, m), 7.55-7.78

(4H, m)

MS (m/z) : 625 (M+H⁺)

Example 2-86

The following compound was obtained in a similar manner to that of Example 2-77.

(±)-3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzoyl}-N-phenethylaminoacetic acid

IR (KBr, cm⁻¹) : 3028, 2931, 1738, 1643, 1599, 1448, 1196

¹H-NMR (CDCl₃, δ) : 1.38-1.95 (4H, m), 1.95-2.45 (2H, m), 2.45-4.30 (9H, m), 6.80-7.00 (2H, m), 7.05-7.77 (18H, m)

MS (m/z) : 597 (M+H⁺)

Example 2-87

The following compound was obtained in a similar manner to that of Example 2-76.

(±)-N-cyanomethyl-3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzamide

IR (KBr, cm⁻¹) : 3320, 3053, 2933, 2251, 1651, 1529, 1296

¹H-NMR (CDCl₃, δ) : 1.50-1.90 (4H, m), 2.10-2.50 (2H, m), 2.58-2.78 (1H, m), 3.10-3.30 (2H, m), 3.98 (1H, dd, J=17.4, 5.7Hz), 4.18 (1H, dd, J=17.4, 6.0Hz), 6.55-6.67 (1H, m), 6.92 (1H, dd, J=4.0, 4.0Hz), 7.25-7.73 (14H, m)

MS (m/z) : 474 (M+H⁺)

Preparation 15

To a solution of phenol (5.01g, 53.2mmol) in toluene (25ml) was added a solution of chlorosulfonyl isocyanate (7.9g, 55.9mmol) in toluene (30ml) at room temperature. The mixture was stirred at 120°C for 14 hours. The solvent was removed in vacuo and the residue was added dropwise to water (75ml). After stirring the resultant mixture at room temperature for 24 hours, the resulting precipitate was collected, washed with water, dissolved in EtOAc, washed with brine successively, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography (hexane:EtOAc, 1:1) to give sulfamic acid phenyl ester (5.52g, 60%).

IR (KBr, cm^{-1}) : 3421, 3309, 1595, 1550, 1489, 1367

$^1\text{H-NMR}$ (CDCl_3 , δ) : 4.99 (2H, brs), 7.26-7.50 (5H, m)

MS (m/z) : 172 (M-H) $^+$

Example 2-88

The following compound was obtained in a the similar manner to that of Example 2-76.

Phenyl (\pm)-{3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzoyl}sulfamate

IR (KBr, cm^{-1}) : 3454, 3059, 2933, 1707, 1593, 1554, 1487, 1444, 1348

$^1\text{H-NMR}$ (CDCl_3 , δ) : 1.25-1.78 (4H, m), 2.00-2.33 (2H, m), 2.33-2.55 (1 H, m), 2.98-3.1 8 (2H, m), 6.75-6.85 (1H, m), 6.90-7.65 (17H, m), 7.75 (1H, d,

$J = 7.8 \text{ Hz}$), 7.87 (1H, s)
MS (m/z) : 591 (M+H⁺)

Example 2-89

The following compound was obtained in a similar manner to that of Example 2-76.

(±)-N-methylsulfony-3-[[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzamide

IR (KBr, cm⁻¹) : 3243, 3032, 2933, 1695, 1604, 1533, 1446, 1402, 1342

¹H-NMR (CDCl₃, δ) : 1.42-2.05 (4H, m), 2.10-2.53 (2H, m), 2.67 (1H, dd, $J = 11.7, 8.0 \text{ Hz}$), 3.08-3.40 (2H, m), 3.25 (3H, s), 6.94 (1H, dd, $J = 3.8, 3.8 \text{ Hz}$), 7.24-7.74 (13H, m), 7.79 (1H, s), 9.22 (1H, br)

MS (m/z) : 511 (M-H)

Preparation 16

To a solution of 1-(3,5-dimethoxybenzyl)-2-(4,5-diphenyloxazol-2-yl)-2-cyclohexene (8.3g) in methylene chloride (100ml) was added boron tribromide (55ml, 1M solution in methylene chloride) at 0°C. After stirring the mixture for 2 hours, the solvent was evaporated in vacuo. The residue was diluted with EtOAc, and the reaction mixture was washed with water and brine. The dried solvent was evaporated in vacuo, and then dissolved in methylene chloride (50ml). To the solution were added trifluoromethanesulfonic acid anhydride (9.3ml) and 2,6-lutidine (8.6ml) at -78°C. After stirring the mixture for 2 hours, the solvent was evaporated in vacuo. The

residue was diluted with EtOAc, and the reaction mixture was washed with water, saturated sodium hydrogencarbonate and brine. The dried solvent was evaporated in vacuo. The residue was purified by chromatography on silica gel to give 1-(3,5-ditrifluoromethanesulfonyloxybenzyl)-2-(4,5-diphenyloxazol-2-yl)-2-cyclohexene (9g).

To a solution of 1-(3,5-ditrifluoromethanesulfonyloxybenzyl)-2-(4,5-diphenyloxazol-2-yl)-2-cyclohexene (9g) in a mixture of ethanol (30ml) and DMF (40ml) was added 1,3-bis(diphenylphosphino)propane (1.8g), palladium acetate (0.96g), and triethylamine (15ml). After stirring the mixture for 5 hours at 80°C under CO atmosphere, the resultant mixture was partitioned between EtOAc and water, and then the organic layer was washed with 1N-hydrochloric acid, saturated sodium hydrogencarbonate, and brine. The dried solvent was evaporated in vacuo. The obtained solid was washed with ether to afford diethyl 5-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}isophthalate (4.1g)

IR (Nujol, cm^{-1}) : 1720

$^1\text{H-NMR}$ (CDCl_3 , δ) : 1.38 (6H, t, $J=8\text{Hz}$), 1.4-2.0 (4H, m), 2.2-2.4 (2H, m), 2.71 (1H, dd, $J=10,12\text{Hz}$), 3.1-3.3 (1H, m), 3.36 (1H, dd, $J=4,12\text{Hz}$), 4.38 (4H, q, $J=8\text{Hz}$), 6.92 (1H, m), 7.2-7.8 (10H, m), 8.22 (2H, $J=2\text{Hz}$), 8.47 (1H, m)

MS (m/z) : 536 ($M+H$) $^+$

Example 3

Diethyl 5-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]-methyl}isophthalate acid was hydrolyzed in a similar manner to that of Preparation 8, and then the resulting compound was

subjected to amide reaction of protected carboxy group in a similar manner to that of Example 1-46 to give 3-[N-(2-phenylethyl)carbamoyl]-5-[[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl]benzoic acid.

IR (Nujol, cm^{-1}) : 1698, 1648

$^1\text{H-NMR}$ (CDCl_3 , δ) : 1.4-2.0 (4H, m), 2.2-2.4 (2H, m),
2.5-3.0 (3H, m), 3.0-3.7 (4H, m), 6.25 (1H, m),
6.93 (1H, m), 7.1-7.5 (10H, m), 7.5-7.8 (2H, m),
8.0-8.2 (1H, m)

MS (m/z) : 583 ($\text{M}+\text{H}^+$)

Example 4

The following compound was obtained in a similar manner to that of Example 2-82.

N-phenethyl-3-[[2-(4,5-diphenyloxazol-2-yl)-1-cyclohexen-1-yl]methyl]benzamide

IR (KBr, cm^{-1}) : 3307, 3059, 3026, 2929, 2858, 1639, 1537,
1444, 1298

$^1\text{H-NMR}$ (CDCl_3 , δ) : 1.45-1.85 (4H, m), 2.05-2.20 (2H, m),
2.58-2.75 (2H, m), 2.84 (2H, t, $J=7.0\text{Hz}$),
3.55-3.70 (2H, m), 4.05 (2H, s), 5.98-6.15 (1H, m),
7.13-7.77 (19H, m)

MS (m/z) : 539 ($\text{M}+\text{H}^+$)

Example 5

The following compound was obtained in a similar manner to that of Example 2-82.

N-phenethyl-3{[2-(4,5-diphenyloxazol-2-yl)-1-cyclopenten-1-yl]methyl}benzamide

IR (KBr, cm^{-1}) : 3286, 3057, 2949, 1635, 1541, 1323

$^1\text{H-NMR}$ (CDCl_3 , δ) : 1.84-2.03 (2H, m), 2.40-2.57 (2H, m),
2.86 (2H, t, $J=7.0\text{Hz}$), 2.90-3.05 (2H, m), 3.58-3.74 (2H, m), 4.17 (2H, s), 6.02-6.14 (1H, m), 7.15-7.77 (19H, m)

MS (m/z) : 525 ($\text{M}+\text{H}^+$)

Preparation 17

A mixture of 3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzoic acid (2.60g, 5.98mmol), triethylamine (1.08ml, 7.77mmol), and diphenylphosphoryl azide (1.67ml, 7.77mmol) in t-butanol-toluene (2:1, 80ml) was stirred at 80°C for 18 hours. After cooling the mixture to room temperature, the mixture was evaporated, diluted with EtOAc, washed with saturated sodium hydrogencarbonate solution, water and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography (hexane:EtOAc, 8:1 elution) to give {3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}phenyl}carbamic acid tert-butyl ester (2.36g, 78%).

IR (KBr, cm^{-1}) : 3327, 2976, 2931, 1728, 1608, 1593,
1531, 1489, 1442

$^1\text{H-NMR}$ (CDCl_3 , δ) : 1.40-1.86 (4H, m), 1.52 (9H, s),
2.05-2.35 (2H, m), 2.52 (1H, dd, $J = 12.8, 10.0\text{ Hz}$),

3.06-3.30 (2H, m), 6.40 (1H, s), 6.86-6.95 (1H, m),
6.95-7.05 (1H, m), 7.15-7.45 (9H, m), 7.57-7.75
(4H, m)

MS (m/z) : 507 (M+H⁺)

Preparation 18

To a solution of {3-[[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}phenyl}carbamic acid tert-butyl ester (2.34g, 4.62mmol) in methylene chloride (25ml) was added trifluoroacetic acid (7ml) at 5°C and the mixture was stirred at room temperature for 1.5 hour. After evaporation, the residue was dissolved in EtOAc, and saturated sodium hydrogencarbonate solution was added thereto under ice-cooling. The mixture was extracted with EtOAc, washed with water and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography (hexane:EtOAc, 3:1 elution) to give 3-[[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}phenylamine (1.74 g, 93%).

IR (KBr, cm⁻¹) : 3454, 3357, 2931, 1603, 1531, 1495,
1444, 1242

¹H-NMR (DMSO-d₆, δ) : 1.30-1.90 (4H, m), 2.03-2.67
(3H, m), 2.92-3.18 (2H, m), 4.97 (2H, s), 6.34-6.55
(3H, m), 6.82-7.02 (2H, m), 7.30-7.55 (6H, m),
7.55-7.70 (4H, m)

MS (m/z) : 407 (M+H⁺)

Preparation 19

To a solution of 3-[[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}phenylamine (500mg, 1.23mmol) in acetic acid (6ml) was added concentrated hydrochloric acid (0.31ml) at 5°C. To the mixture was added a solution of sodium nitrite (94mg, 1.35mmol) in water (0.6ml) and stirred at 5°C for 1 hour. This mixture was added dropwise to a solution of concentrated hydrochloric acid (0.62ml) and copper chloride (37mg, 0.37mmol) in acetic acid (4ml) saturated with sulfur dioxide gas at 5°C. After stirring at room temperature for 1 hour, the reaction mixture was poured into a mixture of EtOAc (100 ml) and water (20ml). The organic layer was washed with water, 1N sodium hydroxide, water and brine, dried over magnesium sulfate, and evaporated in vacuo to give crude 3-[[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}-benzenesulfonyl chloride (463.3mg, 77%). The crude product was immediately used for next transformation without further purification.

Example 6-1

To a solution of 2-phenylethylamine (0.082ml, 0.65mmol) and triethylamine (0.097ml, 0.70mmol) in methylene chloride (3ml) was added a solution of crude 3-[[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzenesulfonyl chloride (213mg, 0.44mmol) in methylene chloride (3ml) at 5°C. After stirring at room temperature for 1 hour, the reaction mixture was diluted with EtOAc, washed with 1N hydrochloric acid, water, saturated sodium hydrogencarbonate solution, water and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography

(hexane:EtOAc, 5:1-3:1 elution) to give 3-{{2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl}methyl}-N-(phenethyl)benzenesulfonamide (54.3mg, 22%).

IR (KBr, cm^{-1}) : 3276, 3059, 3028, 2933, 2862, 1601, 1533, 1446, 1331, 1153

$^1\text{H-NMR}$ (CDCl_3 , δ) : 1.20-1.90 (4H, m), 2.05-2.50 (2H, m), 2.62 (1H, dd, $J = 13.4, 10.5$ Hz), 2.71 (2H, t, $J = 6.7$ Hz), 3.05-3.27 (3H, m), 3.36 (1H, dd, $J = 13.4, 2.9$ Hz), 4.28 (1H, t, $J = 6.3$ Hz), 6.85-7.08 (3H, m), 7.10-7.85 (17H, m)

MS (m/z) : 575 ($M+H^+$)

Example 6-2

To a mixture of 28% ammonia solution (0.7ml) and MeOH (1.0ml) was added a solution of crude 3-{{2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl}methyl}-benzenesulfonyl chloride (253mg, 0.52mmol) in tetrahydrofuran (3ml) at 5°C . After stirring at room temperature for 30 min, the reaction mixture was diluted with EtOAc, washed with 1N hydrochloric acid, water, saturated sodium hydrogencarbonate solution, water and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography (hexane:EtOAc, 2:1 elution) to give 3-{{2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl}methyl}benzenesulfonamide (41.3mg, 17%).

IR (KBr, cm^{-1}) : 3319, 3236, 2935, 1529, 1444, 1306, 1159

$^1\text{H-NMR}$ (DMSO-d_6 , δ) : 1.30-2.00 (4H, m), 2.00-2.45

(2H, m), 2.55-2.75 (1H, m), 2.95-3.15 (1H, m),
3.18-3.40 (1H, m), 6.94 (1H, dd, J = 3.7, 3.7 Hz),
7.20-7.77 (13H, m), 7.85 (1H, s)

MS (m/z) : 471 (M+H⁺)

Example 7-1

To a mixture of (±)-3-[[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}phenylamine (130mg, 0.32 mmol) and 3-phenylpropionic acid (58mg, 0.38mmol) in DMF (4ml) was added 1-hydroxybenzotriazole (65mg, 0.48mmol) and 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide hydrochloride (123mg, 0.64mmol). After stirring the mixture at room temperature for 1 hour, the reaction mixture was diluted with EtOAc, washed with 1N hydrochloric acid, water, saturated sodium hydrogencarbonate solution, water and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography (hexane-EtOAc, 3:1 elution) to give (±)-N-{{3-[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}phenyl}-3-phenylpropionamide (141.4 mg, 82%).

IR (KBr, cm⁻¹) : 3290, 3026, 2931, 2860, 1660, 1608,
1550, 1533, 1485, 1442

¹H-NMR (CDCl₃, δ) : 1.35-1.93 (4H, m), 2.05-2.40 (2H,
m), 2.45-2.75 (3H, m), 2.90-3.30 (4H, m),
6.80-7.65 (17H, m), 7.65-7.77 (4H, m)

MS (m/z) : 539 (M+H⁺)

Example 7-2

The following compound was obtained in a similar manner to that of Example 7-1.

(±)-N-{{3-[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}phenyl}-3-phenylacrylamide

IR (KBr, cm^{-1}) : 3276, 3055, 2931, 2860, 1662, 1626,
1608, 1550, 1487, 1444

$^1\text{H-NMR}$ (CDCl_3 , δ) : 1.40-1.90 (4H, m), 2.10-2.45 (2H, m), 2.58 (1H, dd, $J = 12.5, 9.3$ Hz), 3.10-3.33 (2H, m), 6.47 (1H, d, $J = 15.5$ Hz), 6.92 (1H, dd, $J = 4.0, 4.0$ Hz), 7.05-7.16 (1H, m), 7.18-7.78 (20H, m)

MS (m/z) : 537 ($\text{M}+\text{H}^+$)

Example 7-3

To a solution of (±)-3-{{2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl}methyl}phenylamine (110mg, 0.27mmol) in methylene chloride (3ml) was added benzoylisocyanate (0.038ml, 0.27mmol) at 5°C, and the mixture was stirred at room temperature for 16 hours. To the mixture was added hexane (9ml), and the resulting precipitate was collected, washed with hexane to give (±)-1-benzoyl-3-{{3-{{2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl}methyl}phenyl}urea (114.9mg, 77%).

IR (KBr, cm^{-1}) : 3248, 2935, 1701, 1606, 1562, 1475,
1267, 1225

$^1\text{H-NMR}$ (DMSO-d_6 , δ) : 1.35-1.95 (4H, m), 2.08-2.70
(3H, m), 2.95-3.40 (2H, m), 6.83-6.95 (1H, m),
7.00-7.13 (1H, m), 7.20-7.75 (16H, m),
7.95-8.12(2H, m), 10.85(1H, s), 11.00(1H, s)
MS (m/z) : 554 ($\text{M}+\text{H}^+$)

Example 7-4

To a solution of (\pm)-3- $\{[2-(4,5\text{-diphenyloxazol-2-yl})\text{-2-cyclohexen-1-yl}]\text{methyl}\}$ phenylamine (110mg, 0.27mmol) in methylene chloride (3ml) was added benzylisocyanate (0.17ml, 1.36mmol) at 5 $^{\circ}\text{C}$, and the mixture was stirred at room temperature for 30 min. The reaction mixture was diluted with EtOAc, washed with 1N hydrochloric acid, water, saturated sodium hydrogencarbonate solution, water and brine, dried over magnesium sulfate, and evaporated in vacuo. The resulting solid was collected and washed with EtOAc-hexane to give (\pm)-1-benzyl-3- $\{3-\{[2-(4,5\text{-diphenyloxazol-2-yl})\text{-2-cyclohexen-1-yl}]\text{methyl}\}$ phenyl\}urea (100.7mg, 69%).

IR (KBr , cm^{-1}) : 3302, 3030, 2931, 1635, 1566, 1442, 1238
 $^1\text{H-NMR}$ (DMSO-d_6 , δ) : 1.30-1.95 (4H, m), 2.05-2.70
(3H, m), 2.94-3.23 (2H, m), 4.32(2H, d, $J=6.0\text{Hz}$),
6.58(1H, t, $J=6.0\text{Hz}$), 6.77-6.95 (2H, m), 7.08-7.53
(14H, m), 7.53-7.73 (4H, m), 8.56 (1H, s)
MS (m/z) : 540 ($\text{M}+\text{H}^+$)

Example 7-5

To a solution of (\pm)-3- $\{[2-(4,5\text{-diphenyloxazol-2-yl})\text{-2-}$

cyclohexen-1-yl)methyl}phenylamine (110mg, 0.27mmol) in methylene chloride (3ml) was added benzenesulfonylisocyanate (0.037ml, 0.27mmol) at 5°C, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was evaporated, and the residue was purified by silica gel column chromatography (methylene chloride-MeOH, 30:1 elution) to give (±)-1-benzenesulfonyl-3-{3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl)methyl}phenyl}urea (159.0mg, 100%).

IR (KBr, cm^{-1}) : 3338, 2933, 1689, 1612, 1595, 1552 1487,
1446, 1346, 1242

$^1\text{H-NMR}$ (CDCl_3 , δ) : 1.35-1.95 (4H, m), 2.05-2.43
(2H, m), 2.43-2.63 (1H, m), 3.09-3.34(2H, m),
6.86-6.96 (1H, m), 7.05-7.75 (18H, m), 7.83-7.99
(2H, m), 8.37 (1H, br s)

MS (m/z) : 590 ($\text{M}+\text{H}^+$)

Example 7-6

To a mixture of (±)-3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl)methyl}phenylamine (110mg, 0.27mmol) and pyridine (0.066ml, 0.81mmol) in methylene chloride (3ml) was added benzylsulfonyl chloride (78mg, 0.41mmol) at 5°C. The mixture was stirred at the same temperature for 30 min, then stirred at room temperature for 30 min. The reaction mixture was diluted with EtOAc, washed with 1N hydrochloric acid, water, saturated sodium hydrogencarbonate solution, water and brine, dried over magnesium sulfate, and evaporated in vacuo. The residue was purified by silica gel column chromatography (hexane-EtOAc, 5:1 elution) to give (±)-N-3-{[2-(4,5-

diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}phenyl}benzylsulfonamide (99.2mg, 65%).


IR (KBr, cm^{-1}) : 3251, 3033, 2931, 1604, 1589, 1496, 1444, 1400, 1338, 1244, 1151

$^1\text{H-NMR}$ (CDCl_3 , δ) : 1.42-1.92 (4H, m), 2.10-2.45 (2H, m), 2.56 (1H, dd, $J=13.0, 10.3\text{Hz}$), 3.10-3.38 (2H, m), 4.30 (2H, m), 6.16 (1H, s), 6.90-7.45 (16H, m), 7.53-7.75 (4H, m)

MS (m/z) : 561 ($\text{M}+\text{H}^+$)

C L A I M S

1. A compound of the formula :



(I)

wherein

R¹ is aryl which may be substituted with halogen(s),

R² is aryl which may be substituted with halogen(s),

X is single bond, $\text{C}(=\text{O})$ or SO_2 ,

R³ and R⁴ are independently hydrogen or suitable substituent,

(wherein X is $\text{C}(=\text{O})$, neither R³ nor R⁴ is hydrogen),

R³ and R⁴ may be linked together to form $-\text{N}(\text{ring})-$,

$-\text{N}(\text{ring})-$ is N-containing heterocyclic group which may be substituted with one or more suitable substituent(s),

R⁵ is

- (1) hydrogen,
- (2) hydroxy,
- (3) carboxy, or
- (4) protected carboxy,

A¹ is lower alkylene or single bond,

(A²) is cyclo(C₃-C₉)alkane or cyclo(C₅-C₉)alkene,

or a pro-drug thereof, or a pharmaceutically acceptable salt thereof.

2. A compound according to the claim 1,

wherein

R¹ is aryl which may be substituted with halogen(s),

R² is aryl which may be substituted with halogen(s),

X is single bond, $\text{C}=\text{O}$ or SO₂,

R³ and R⁴ are independently

(1) hydrogen;

(2) hydroxy;

(3) lower alkyl which may be substituted with one or more substituent(s) selected from the group consisting of:

(a) hydroxy,

(b) cyano,

(c) lower alkoxy,

(d) hydroxy(lower)alkoxy,

(e) cyclo(lower)alkyl,

(f) cyclo(lower)alkenyl,

(g) amino,

(h) lower alkylamino,

(i) carbamoyl,

(j) carboxy,

(k) protected carboxy,

(l) heterocyclic group optionally substituted with ar(lower)alkyl or oxo, and

- (m) aryl optionally substituted with
 - hydroxy,
 - carboxy,
 - protected carboxy,
 - carboxy(lower)alkyl, or
 - lower alkoxy which may be substituted with carboxy or protected carboxy;
- (4) lower alkoxy which may be substituted with aryl(s);
- (5) aryl which may be substituted with one or more substituent(s) selected from the group consisting of:
 - (a) aryloxy,
 - (b) acylamino, and
 - (c) carbamoyl;
- (6) cyclo(lower)alkyl which may be substituted with hydroxy(s);
- (7) arylsulfonyl;
- (8) ar(lower)alkylsulfonyl;
- (9) lower alkylsulfonyl;
- (10) aryloxysulfonyl;
- (11) heterocyclic group which may be substituted with one or more substituent(s) selected from the group consisting of:
 - (a) ar(lower)alkyl,
 - (b) aryl,
 - (c) protected carboxy,
 - (d) lower alkyl, and
 - (e) oxo;
- (12) acyl which may be substituted with aryl; or
- (13) carbamoyl which may be substituted with acyl, ar(lower)alkyl, or arylsulfonyl,

(wherein X is $\text{C}=\text{O}$, neither R^3 nor R^4 is hydrogen),

R^3 and R^4 may be linked together to form $-\text{N}$ (ring),

$-\text{N}$ (ring) is N-containing heterocyclic group which may be substituted with one or more substituent(s) selected from the group consisting of:

- (1) lower alkyl,
- (2) aryl,
- (3) protected carboxy,
- (4) hydroxy(lower)alkyl,
- (5) ar(lower)alkyl,
- (6) hydroxy,
- (7) oxo, and
- (8) lower alkylamino,

R^5 is

- (1) hydrogen,
- (2) hydroxy,
- (3) carboxy, or
- (4) protected carboxy,

A^1 is lower alkylene or single bond,

A^2 (ring) is cyclo(C_3 - C_9)alkane or cyclo(C_5 - C_9)alkene,

or a pro-drug thereof, or a pharmaceutically acceptable salt thereof.

3. A compound according to the claim 1,

wherein

R^1 is aryl,

R^2 is aryl,

X is single bond, $\overset{\overset{\text{C}}{\parallel}}{\text{O}}$ or SO_2 ,

R^3 and R^4 are independently

(1) hydrogen;

(2) hydroxy;

(3) lower alkyl which may be substituted with one or more substituent(s) selected from the group consisting of:

(a) hydroxy,

(b) cyano,

(c) lower alkoxy,

(d) hydroxy(lower)alkoxy,

(e) cyclo(lower)alkyl,

(f) cyclo(lower)alkenyl,

(g) amino,

(h) lower alkylamino,

(i) carbamoyl,

(j) carboxy,

(k) protected carboxy,

(l) heterocyclic group optionally substituted with ar(lower)alkyl or oxo, and

(m) aryl optionally substituted with

hydroxy,

carboxy,

protected carboxy,

carboxy(lower)alkyl, or

lower alkoxy which may be substituted with carboxy or protected carboxy;

(4) lower alkoxy which may be substituted with aryl(s);

(5) aryl which may be substituted with one or more

substituent(s) selected from the group consisting of:

- (a) aryloxy,
 - (b) acylamino, and
 - (c) carbamoyl;
 - (6) cyclo(lower)alkyl which may be substituted with hydroxy(s);
 - (7) arylsulfonyl;
 - (8) ar(lower)alkylsulfonyl;
 - (9) lower alkylsulfonyl;
 - (10) aryloxysulfonyl;
 - (11) heterocyclic group which may be substituted with one or more substituent(s) selected from the group consisting of:
 - (a) ar(lower)alkyl,
 - (b) aryl,
 - (c) protected carboxy,
 - (d) lower alkyl, and
 - (e) oxo;
 - (12) acyl which may be substituted with aryl; or
 - (13) carbamoyl which may be substituted with acyl, ar(lower)alkyl, or arylsulfonyl,
- (wherein X is $\text{C}=\text{O}$, neither R^3 nor R^4 is hydrogen),

R^3 and R^4 may be linked together to form $-\text{N} \bigcirc$,

$-\text{N} \bigcirc$ is N-containing heterocyclic group which may be substituted with one or more substituent(s) selected from the group consisting of:

- (1) lower alkyl,
- (2) aryl,
- (3) protected carboxy,

(4) hydroxy(lower)alkyl,

(5) ar(lower)alkyl,

(6) hydroxy,

(7) oxo, and

(8) lower alkylamino,

R⁵ is hydrogen,

A¹ is lower alkylene,

A² is

(1) cyclohexane,

(2) cyclohexene,

(3) cyclopentane, or

(4) cyclopentene,

or a pro-drug thereof, or a pharmaceutically acceptable salt thereof.

4. A compound according to the claim 1,

wherein

R¹ is phenyl,

R² is phenyl,

X is $\begin{array}{c} \text{C} \\ \parallel \\ \text{O} \end{array}$ or SO₂,

R³ and R⁴ are independently

(1) hydrogen;

(2) lower alkyl which may be substituted with one or more substituent(s) selected from the group consisting of:

(a) hydroxy,

(b) heterocyclic group, and

- (c) phenyl;
 (3) lower alkoxy which may be substituted with phenyl;
 or
 (4) phenyl which may be substituted with phenyloxy;
 (wherein X is $\text{C}=\text{O}$, neither R^3 nor R^4 is hydrogen),

R^3 and R^4 are linked together to form $-\text{N} \bigcirc$,

$-\text{N} \bigcirc$ is N-containing heterocyclic group;

R^5 is hydrogen,

A^1 is methylene,

A^2 is


- (1) cyclohexane,
- (2) cyclohexene,
- (3) cyclopentane, or
- (4) cyclopentene,

or a pro-drug thereof, or a pharmaceutically acceptable salt thereof.

5. A compound according to the claim 1,

wherein said compound is N-[(2-hydroxy-2-phenyl)ethyl]-3-
 {[(1S,2R)-2-(4,5-diphenyloxazol-2-yl)-1-
 cyclopentyl]methyl}benzamide, N-(2,2-diphenylethyl)-3-
 {[(1S,2R)-2-(4,5-diphenyl-oxazol-2-yl)-1-
 cyclopentyl]methyl}benzamide, N-benzyloxy-3-
 {[(1S)-2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}benzamide or
 N-benzylsulfonyl-3-
 {[(1S)-2-(4,5-diphenyloxazol-2-yl)-2-
 cyclohexen-1-yl]methyl}benzamide.

6. A process for preparing the compound of the formula (I):



(I)

wherein

R¹ is aryl which may be substituted with halogen(s),

R² is aryl which may be substituted with halogen(s),

X is single bond, $\text{C}(=\text{O})$ or SO_2 ,

R³ and R⁴ are independently hydrogen or suitable substituent,

(wherein X is $\text{C}(=\text{O})$, neither R³ nor R⁴ is hydrogen),

R³ and R⁴ may be linked together to form -N \bigcirc ,

-N \bigcirc is N-containing heterocyclic group which may be substituted with one or more suitable substituent(s),

R⁵ is

- (1) hydrogen,
- (2) hydroxy,
- (3) carboxy, or
- (4) protected carboxy,

A¹ is lower alkylene or single bond,


A² is cyclo(C₃-C₉)alkane or cyclo(C₅-C₉)alkene,

or a pro-drug thereof, or a pharmaceutically acceptable salt

thereof,


which comprises,

(1) reacting a compound of the formula (II):




(II)

wherein R^1, R^2, R^5, A^1 , and A^2 are each as defined above, or a salt thereof with a compound of the formula (III):



(III)


wherein R^3 and R^4 are each as defined above, or its reactive derivative at the amino group or a salt thereof to give a compound of the formula (IV):



(IV)


wherein $R^1, R^2, R^3, R^4, R^5, A^1$, and A^2 are each as defined above, or a pro-drug thereof, or a pharmaceutically acceptable salt thereof; or

(2) reacting a compound of the formula (V):




(V)

wherein R^1, R^2, R^5, A^1 , and A^2 are each as defined above,
 Y is halogen,
 or a salt thereof with a compound of the formula (III):



(III)


wherein R^3 and R^4 are each as defined above, or its reactive derivative at the amino group or a salt thereof to give a compound of the formula (VI):




(VI)

wherein $R^1, R^2, R^3, R^4, R^5, A^1$, and A^2 are each as defined above, or a pro-drug thereof, or a pharmaceutically acceptable salt thereof; or


(3) reacting a compound of the formula (VII):



wherein R^1, R^2, R^5, A^1 , and A^2 are each as defined above, or a salt thereof with a compound of the formula (VIII):




wherein R^{4a} is acyl which may be substituted with aryl, or its reactive derivative at the carboxy group or a salt thereof to give a compound of the formula (IX):




wherein $R^1, R^2, R^{4a}, R^5, A^1$, and A^2 are each as defined above, or a pro-drug thereof, or a pharmaceutically acceptable salt

thereof; or


(4) reacting a compound of the formula (VII):



wherein R^1 , R^2 , R^5 , A^1 , and A^2 are each as defined above, or a salt thereof with a compound of the formula (X):




wherein R^6 is acyl or hydroxy, or a salt thereof to give a compound of the formula (XI):




wherein R^1 , R^2 , R^5 , R^6 , A^1 , and A^2 are each as defined above, or a pro-drug thereof, or a pharmaceutically acceptable salt thereof; or


(5) reacting a compound of the formula (VII):



wherein R^1 , R^2 , R^5 , A^1 , and A^2 are each as defined above, or a salt thereof with a compound of the formula (XII):



wherein R^7 is lower alkyl, ar(lower)alkyl or aryl, or its reactive derivative at the sulfo group or a salt thereof to give a compound of the formula (XIII):



wherein R^1 , R^2 , R^5 , R^7 , A^1 , and A^2 are each as defined above, or a pro-drug thereof, or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition which comprises, as an active ingredient, a compound of claim 1 or a pharmaceutically acceptable salt thereof in admixture with pharmaceutically

acceptable carriers.

8. A use of the composition of claim 1 as a medicament.
9. A use of the composition of claim 1 as an agonist or an antagonist of PGE₂-sensitive receptor.
10. A method for treating or preventing PGE₂ mediated diseases which comprises administering an effective amount of a composition of claim 1 to human beings or animals.
11. A method for treating or preventing inflammatory conditions, various pains, collagen diseases, autoimmune diseases, various immunity diseases, analgesic, thrombosis, allergic disease, cancer or neurodegenerative diseases which comprises administering an effective amount of a composition of claim 1 to human beings or animals.
12. A use of the composition of claim 1 for the manufacture of a medicament for treating or preventing PGE₂ mediated diseases in human beings or animals.
13. A use of the PGE₂ antagonist for the manufacture of a medicament for treating or preventing mesangial proliferative glomerulonephritis.
14. A use according to claim 12, wherein PGE₂ antagonist is EP4 receptor blocker.
15. A use according to claim 12 or 13, wherein PGE₂ antagonist

is a compound of the claim 1.

INTERNATIONAL SEARCH REPORT

Internal Application No.

PCT/JP 99/05212

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D263/32 C07D413/10 A61K31/421 A61K31/422 C07D413/12

According to International Patent Classification (IPC) or to both national classification and IPC

8. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 17393 A (FUJISAWA PHARMACEUTICAL CO) 29 June 1995 (1995-06-29) cited in the application claims ---	1-15
X	WO 97 03973 A (FUJISAWA PHARMACEUTICAL CO.,LTD) 6 February 1997 (1997-02-06) cited in the application claims ---	1-15
A	US 3 901 908 A (FITZI KONRAD ET AL) 26 August 1975 (1975-08-26) the whole document ---	1-15
P,X	WO 98 55468 A (FUJISAWA PHARMACEUTICAL CO.,LTD) 10 December 1998 (1998-12-10) claims ---	1-15

-/--

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

^a Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P": document published prior to the International filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention.

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

12 January 2000

Date of mailing of the international search report

20/01/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Henry, J

INTERNATIONAL SEARCH REPORT

International Application No

PCT/JP 99/05212

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>WO 99 21843 A (FUJISAWA PHARMACEUTICAL CO., LTD) 6 May 1999 (1999-05-06) claims</p> <p>-----</p>	1-15

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP 99/05212

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 10-11
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 10-11
are directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP 99/05212

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9517393	A	29-06-1995	AU 686286 B	05-02-1998
			AU 1200695 A	10-07-1995
			CA 2179399 A	29-06-1995
			CN 1138328 A	18-12-1996
			CN 1229795 A	29-09-1999
			EP 0736018 A	09-10-1996
			HU 76341 A	28-08-1997
			JP 9506894 T	08-07-1997
WO 9703973	A	06-02-1997	AU 6469796 A	18-02-1997
			CN 1196726 A	21-10-1998
			EP 0842161 A	20-05-1998
			HU 9900881 A	30-08-1999
			JP 11509191 T	17-08-1999
			US 5972965 A	26-10-1999
US 3901908	A	26-08-1975	NONE	
WO 9855468	A	10-12-1998	NONE	
WO 9921843	A	06-05-1999	AU 9282398 A	17-05-1999